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Abstract of the Dissertation 
 
Skeletal Muscle Impairments in People with Diabetes and Peripheral Neuropathy 
 
by 
 
Lori Jeanne Tuttle 
 
Doctor of Philosophy in Movement Science 
 
Washington University in St. Louis, 2011 
 
Dr. Michael J. Mueller, Chairperson 
 
  
 Diabetes mellitus (DM) is a chronic disease that affects almost 24 million people 
and has large socioeconomic costs.  Of these 24 million people, 60-70 % will develop 
some form of nervous system impairment, including peripheral neuropathy (PN). It is 
important to understand muscle structure and impairments in people with DM+PN in 
order to determine appropriate interventions to limit the disability that is associated with 
DM+PN. The objectives of this research are to describe skeletal muscle structure in 
people with DM+PN, to determine whether neuropathic muscle structure and 
composition are associated with movement impairments and functional limitations, and 
whether neuropathic muscle can be modulated by activity level and/or an exercise 
intervention. 
 In Chapter 2, we examine whether intermuscular adipose tissue (IMAT) volumes 
are different between groups with DM, DM+PN, and a group without DM or PN 
(NoDMPN).  We report that there is no difference in IMAT volumes in these groups, but 
that increased IMAT is associated with poorer physical performance and the DM+PN 
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group had the lowest measures of physical performance.  In Chapter 3, we examine 
whether activity level in people with DM+PN is associated with IMAT. We report that 
activity level is inversely associated with IMAT volumes.  In Chapter 4, we examine 
whether an exercise intervention for people with DM+PN is able to improve function and 
change IMAT and muscle volumes.  We report that our duration-based exercise program 
was successful in increasing 6 minute walk distance, but there was no change in IMAT or 
muscle volumes.  In Chapter 5, we provide a case report detailing an exercise 
intervention for a specific individual with DM+PN who was able to increase his average 
activity level and shows improvement in muscle performance and physical function. 
 Overall, our results suggest that people with DM+PN have lower levels of 
physical performance than their peers and increased IMAT is associated with poor 
physical performance.  Increased activity levels are associated with decreased IMAT 
volume.  People with DM+PN are able to safely increase their walking distance following 
an exercise intervention, but we did not see a change in muscle composition.  Additional 
research is needed to determine the specific roles of IMAT in skeletal muscle and 
function.  
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Chapter 1: 
Background and Significance 
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 Diabetes mellitus is a chronic disease that affects almost 24 million people 
(diagnosed and undiagnosed), results in significant physical disability, and creates large 
socio-economic costs.1 The effects of diabetes mellitus on body composition and muscle 
structure and impairments may explain the impaired physical function associated with 
diabetes mellitus.  Peripheral neuropathy is a frequent complication of diabetes mellitus 
and is associated with lower extremity sensory disturbances, muscle weakness, and 
functional deficits.  People with diabetes and peripheral neuropathy display an abnormal 
infiltration of fat in the intra- and extra-cellular compartments of their lower extremity 
musculature that is not noted in their peers.2,3, 4,5  The extent to which neuropathy in 
particular contributes to this fatty infiltration is unknown.  It is also unknown whether 
fatty infiltration in the muscle contributes to muscle weakness and if so, whether the fat 
infiltration and muscle weakness can be reversed or attenuated through exercise or other 
interventions.  Magnetic resonance imaging (MRI) has the potential to increase our 
understanding of muscle composition and dysfunction and to help optimize rehabilitation 
strategies.  The mechanism for decreased physical function in people with diabetes is 
important for physical therapists and other health care providers to understand so that the 
optimal rehabilitation strategies for the recovery of muscle function can be determined in 
order to reverse or prevent further disability. In this introductory chapter, I will briefly 
overview muscle structure and impairments in DM and PN, the relationship of IMAT to 
physical function, and the effect of exercise on IMAT. 
 
Muscle Structure and Impairments in Diabetes and Peripheral Neuropathy 
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 The incidence and prevalence of diabetes mellitus and complications related to 
diabetes mellitus are reaching epidemic levels.1 Comorbidities and conditions that are 
often related to diabetes such as obesity,6,7 heart disease,6,7,8  stroke,7  and arthritis,7 have 
been identified as contributors to disability in people with diabetes.9, 10  The effects of 
diabetes mellitus on body composition (muscle adaptations in particular) as well as  
muscle function are now being examined as contributors to  the impaired physical 
function that is associated with diabetes.9- 11  
 Sixty to 70 percent of individuals with diabetes mellitus have mild to severe 
forms of nervous system disease.1 Individuals with diabetes and peripheral neuropathy 
develop sensory loss as well as muscle weakness and motor dysfunction.12 Andersen et 
al.13 reported strength losses of ~21% in the ankle musculature of individuals with 
diabetes mellitus.  The severity of peripheral neuropathy has been associated with muscle 
weakness in type 1 and type 2 diabetes mellitus.14  In another study, Andersen et al.12 
used magnetic resonance imaging (MRI) to demonstrate that muscle atrophy underlies 
motor weakness of the distal extremities in individuals with diabetes mellitus and 
peripheral neuropathy.  However, the effect of diabetes mellitus and peripheral 
neuropathy on muscle quality remains a topic of interest because most individuals with 
diabetes mellitus do not display noticeable muscle atrophy despite muscle weakness 
compared to individuals without diabetes mellitus.  The Health, Aging, and Body 
Composition study verified that arm and leg muscle mass do not accurately predict 
muscle strength for older adults with diabetes mellitus.9  They studied 485 older adults 
with diabetes mellitus that had larger arm and leg muscle mass than those persons 
without diabetes and found that diabetes is associated with lower strength and muscle 
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quality (defined as muscle strength per unit regional muscle mass, assessed by DXA), 
and may contribute to the development of disability in older adults with diabetes 
mellitus.9 Another Health, Aging, and Body Composition study was the first to report 
data on how muscle mass and strength in people with diabetes mellitus change over 
time.10 These data showed that individuals with diabetes mellitus experience a greater 
loss of muscle strength and quality than people without diabetes mellitus.10 Despite the 
high prevalence of diabetes and peripheral neuropathy and their potentially devastating 
effects on strength and function, little is known about neuropathic skeletal muscles and 
their impact on function or their ability to adapt to an exercise program. 
 Goodpaster et al.5 showed that accumulation of adipose tissue (measured by 
computed tomography) within the fascia surrounding skeletal muscle in the thigh is 
associated with insulin resistance.  Goodpaster et al.2 performed a subsequent study to 
examine whether skeletal muscle fat is characteristic of elderly individuals with diabetes, 
hyperinsulinemia, and impaired glucose tolerance.  Subcutaneous thigh fat was similar, 
however intermuscular adipose tissue (IMAT) was higher in the people with diabetes and 
impaired glucose tolerance.2 Intermuscular adipose tissue (IMAT) is defined as the 
visible adipose tissue beneath muscle fascia and between muscle groups (Figure 1).15,16   
IMAT has been linked to insulin resistance, and has been described as a unique adipose 
tissue depot that is similar to visceral adipose tissue in its risks for metabolic 
impairment.2,4,17 They concluded that people with increased amounts of IMAT may be at 
increased risk for metabolic disease, including diabetes mellitus.2  
 Because adipose tissue is associated with metabolic impairments, decreased 
muscle function, and diabetes, investigators pursued the use of MRI methods to quantify 
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the amount of lipid within the muscle.17, 18,19  MRI allows for non-invasive, quantitative, 
and reliable measurements of quantifying IMAT.18 In addition, the inherent contrast 
between different tissue types within the body when viewed via MRI make MRI an  
excellent technique for morphometric measures of skeletal muscle.  
 
Relationship of IMAT to physical function 
   In our previous work, we have shown that a group with obesity, diabetes, and 
peripheral neuropathy had significantly greater amounts of IMAT in the calf compared to 
a non-obese control group and that this IMAT was associated with poor physical 
performance.11  It is unclear to what extent obesity contributes to this accumulation of 
IMAT in skeletal muscle and to what extent the independent factors of  diabetes and 
peripheral neuropathy contribute to the amount of IMAT.  In addition, the relationship 
between IMAT and physical performance is not clear in these groups.  Previous 
investigators4,17 have shown that IMAT is linked to insulin resistance and that 
denervation20 can also contribute to fat infiltration in muscle, but it is unclear whether 
obesity alone accounts for a significant portion of IMAT infiltration. 
  It is also unknown whether IMAT accumulation is muscle or muscle 
compartment specific, i.e. whether one muscle or a group of muscles tends to have more 
IMAT than others. Different muscles in the calf have different amounts of fast twitch and 
slow twitch fibers. For example, the gastrocnemius muscle is considered largely a fast 
twitch muscle and is used more for large force production, while the soleus muscle is 
considered more slow twitch and is a postural muscle that is better suited for using lipids 
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as a fuel source.21 It is unknown whether different “types” of muscles are more affected 
by IMAT infiltration in the presence of diabetes, diabetes and neuropathy, and obesity.  
 Increased physical activity has been shown to decrease pain and improve balance 
in people with diabetes and peripheral neuropathy.22,23 Improved physical activity is 
particularly important for people with diabetes, not only for improved glucose control 
and cardiovascular fitness, but also because people with diabetes are two times more 
likely to have limitations in physical mobility and this likelihood for physical mobility 
limitations increases in the presence of peripheral neuropathy.23  The mechanisms for 
physical mobility limitations in diabetes are unclear. IMAT has been linked to 
immobilization in healthy young adults24 and has been shown to be reduced with exercise 
in a population with diabetes and without peripheral neuropathy,25 indicating that 
physical activity may be a potent modifier of IMAT content in skeletal muscle.  IMAT 
has also been shown to be higher in the affected limb in people with chronic stroke26 and 
spinal cord injury.27 IMAT has been shown to be higher in  rotator cuff injury with nerve 
involvement20 indicating that nerve dysfunction (such as peripheral neuropathy) could 
impact IMAT. 
 
Effect of Exercise on IMAT 
 The benefits of exercise to help control diabetes mellitus and reduce subsequent 
complications are well known and accepted.28,29    Besides improved diabetes control and 
lower mortality rates, walking and increased activity appear to improve complications 
from peripheral neuropathy.22  The evidence of the benefits of exercise for people with 
diabetes has led the American Diabetes Association (ADA) and the American College of 
7 
 
Sports Medicine (ACSM) to recommend that adults with diabetes participate in at least 
30 minutes per day of moderate-intensity physical activity, but the effects of this exercise 
program are untested in people with diabetes and peripheral neuropathy.30   
 IMAT in the thigh has been shown to reduce in size in response to increases in 
activity and exercise programs in an older population31 as well as in a group with 
diabetes, but no peripheral neuropathy,25 but it is unclear whether an exercise program 
can impact IMAT in the calf in a population with diabetes and peripheral neuropathy. 
Although people with diabetes and peripheral neuropathy clearly have lower extremity 
impairments, little evidence exists to determine if these impairments can improve with 
exercise.  Studies investigating the effect of strengthening exercise have reported only 
modest improvements32,33 and a Cochrane review of the literature concluded that there is 
inadequate evidence to evaluate the effect of strengthening exercise for people with 
diabetes and peripheral neuropathy.34  
 While there are a number of studies to support the beneficial effects of exercise in 
people with diabetes, there is little information about how exercise will affect the muscle 
of people with diabetes and peripheral neuropathy.  Previous studies have demonstrated 
that IMAT levels are increased in the presence of insulin resistance and diabetes, but it is 
unclear whether this adipose tissue can adapt to exercise in the presence of diabetes and 
peripheral neuropathy.  A greater knowledge is needed to determine the muscular 
impairments that exist in people with diabetes and peripheral neuropathy and whether or 
not these impairments can be modified by an exercise intervention.  
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 Mueller and Maluf35 have proposed a Physical Stress Theory for rehabilitation 
speculating that essentially all biological tissues adapt to the stresses placed upon them, 
provided the stresses are not above a threshold that would cause injury.  Based on this 
theory, neuropathic muscle and skin should be able to adapt to increased activity and an 
exercise program.  It is not clear what the appropriate magnitude and duration of activity 
and exercise is necessary and safe to cause adaptation in neuropathic muscle and skin.     
 
PRIMARY PURPOSE: The objectives of this research are to describe skeletal muscle 
structure in people with diabetes and peripheral neuropathy, to determine whether 
neuropathic muscle structure and composition are associated with movement 
impairments and functional limitations, and whether neuropathic muscle can be 
modulated by activity level and/or an exercise intervention. 
SPECIFIC AIMS AND HYPOTHESES 
 
Specific Aim 1: (Chapter 2) 
To determine differences in muscle structure and composition (IMAT, muscle volume) in 
specific calf muscles (gastrocnemius, soleus) and calf compartments (anterior, lateral, 
deep) between people with diabetes and peripheral neuropathy (DM+PN), people with 
diabetes and no peripheral neuropathy (DM), and people without diabetes and without 
peripheral neuropathy (NoDMPN). Additionally, the relationship between calf muscle 
structure and composition and measures of muscle performance (peak torque) and 
physical function (PPT, 6 minute walk test, stair power) will be examined.  
 Hypothesis 1: People with DM+PN and people with DM will have greater 
 amounts of IMAT, and similar calf muscle volumes compared to the NoDMPN 
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 group and the  DM+PN group will display the largest amounts of IMAT of all 3 
 groups. 
 Hypothesis 2: The soleus muscle will display more IMAT than the gastrocnemius 
 muscle in people with DM+PN and people with DM. 
 Hypothesis 3: IMAT will be negatively correlated with peak torque and measures 
 of physical function. 
Specific Aim 2: (Chapter 3) 
To characterize activity levels (average daily step count) in people with DM+PN and to 
determine relationships between activity level and IMAT volume in the calf, calf muscle 
volume, muscle performance, physical function, and glucose control. 
 Hypothesis 1: People with DM+PN will take around 5,000 steps per day based on 
 prior observations and reports. 
 Hypothesis 2: Higher average daily step count will be associated with lower 
 IMAT  volume, larger muscle volume, improved glucose control (lower HbA1c 
 levels), higher  muscle performance, and higher physical function. 
Specific Aim 3: (Chapters 4&5) 
To determine the effect of a three month progressive exercise program on calf muscle 
structure and composition (IMAT, muscle volume), muscle performance (peak torque), 
and functional limitations (Physical Performance Test, 6 minute walk test) in people with 
DM+PN who complete the 3 months of training (EX) and compare these outcomes to a 
group of people with DM+PN who do not complete the training (CON). 
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 Hypothesis 1: The EX group will display decreased IMAT in calf muscles and 
 increased calf muscle volume after a  progressive exercise program 
 compared to the CON group. 
 Hypothesis 2: The EX group will display increased dorsiflexor and plantarflexor 
 peak torque and improved measures of functional limitation after a progressive 
 exercise program compared to the CON group. 
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Figure 1.  Panels A and C are cross sections of the calf via MRI. Notice that 
subcutaneous adipose tissue and intermuscular adipose tissue are intact.  Panels B and D 
are the same cross sections with the subcutaneous adipose tissue removed leaving the 
intermuscular adipose tissue and calf muscle. Panels A and B are images from a person 
with diabetes and panels C and D are images from a person with diabetes and peripheral 
neuropathy. 
A.  B.  
C. D.  
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Chapter 2 
Intermuscular Adipose Tissue is Associated with Poor Functional Performance and 
is Muscle Specific 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in review: 
Tuttle LJ, Sinacore DR, Mueller MJ. Intermuscular Adipose Tissue is Associated with 
Poor Functional Performance and is Muscle Specific. J Diabetes Complications.  
17 
 
ABSTRACT 
Purpose: People with obesity, diabetes, and peripheral neuropathy have high levels of 
intermuscular adipose tissue (IMAT) volume which has been inversely related to physical 
function. The primary purpose of this study was to determine if physical function and calf 
IMAT are different between groups with diabetes mellitus (DM), DM and peripheral 
neuropathy (DM+PN) and a group without DM or PN (NoDMPN).   
Methods: We studied 45 people; 11 with type 2 diabetes, 24 with diabetes and peripheral 
neuropathy, and 10 age and BMI matched people without diabetes and without peripheral 
neuropathy and measured physical function (6 minute walk, Physical Performance Test, 
stair power), muscle performance and muscle morphology (calf muscle volume, calf 
IMAT). 
Results: There were group differences for measures of physical performance: six minute 
walk distance, physical performance test, and stair power (P<0.05).  There were no 
differences between groups in measures of calf muscle or calf IMAT volumes. Calf 
IMAT infiltration was muscle and compartment specific. The gastrocnemius muscle had 
a higher ratio of IMAT/Muscle volume than any other muscle or compartment 
[0.286(0.37) (gastrocnemius) vs. 0.131(0.13) (soleus) vs. 0.154(0.16) (anterior 
compartment)]. Calf IMAT was inversely related to physical performance on the 6 
minute walk test (r=-0.47), and the physical performance test (r=-0.36).  IMAT/Muscle 
volume was inversely related to physical performance (PPT r=-0.44, 6MW r=-0.48, Stair 
Power r= -0.30). 
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Conclusions: Calf IMAT volume, diabetes and peripheral neuropathy are associated with 
poor physical performance and calf IMAT may be muscle or compartment specific. 
Key Words: physical performance, peripheral neuropathy, Intermuscular Adipose Tissue 
(IMAT)
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Introduction 
 Previous research has shown that a group of people with obesity, diabetes, and 
peripheral neuropathy had significantly greater amounts of intermuscular adipose tissue 
(IMAT) in the calf compared to a non-obese control group and that this calf IMAT was 
associated with poor physical performance (Hilton et al., 2008).  IMAT is defined as the 
visible adipose tissue beneath muscle fascia and between muscle groups (Lawler et al., 
2003 and Ruan et al. 2007).  The unique contributions of obesity, diabetes, and diabetes 
and peripheral neuropathy to the amount of IMAT in skeletal muscle are not clear.  In 
addition, the relationship between calf IMAT and physical performance is not clear in 
these groups.  IMAT in the thigh has been linked to insulin resistance, and has been 
described as a unique adipose tissue depot that is similar to visceral adipose tissue in its 
risks for metabolic impairment (Goodpaster et al., 2003, Goodpaster et al., 2000 and 
Gallagher et al., 2005).  Previous investigators (Goodpaster et al. 2000 and Gallagher et 
al., 2005) have shown that IMAT is linked to insulin resistance and that denervation 
(Rowshan et al., 2010) can also contribute to fat infiltration in muscle, but it is unclear 
how the combination of diabetes, peripheral neuropathy and obesity impact IMAT 
infiltration. 
  It is also unknown whether calf IMAT accumulation is muscle or muscle 
compartment specific, i.e. whether one muscle or a group of muscles tends to have more 
IMAT than others. Muscles in the calf have different distributions of fast twitch and slow 
twitch fibers. For example, the gastrocnemius muscle is considered predominantly a fast 
twitch muscle and is used more for large force production, while the soleus muscle is 
considered more slow twitch and is a postural muscle that is better suited for using lipids 
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as a fuel source (Edgerton et al., 1975). It is unknown whether muscles with different 
“predominance” of fiber types are targeted by IMAT infiltration in the presence of 
diabetes, diabetes and neuropathy, and obesity.  
 Therefore, the purposes of this study were a) to determine differences in physical 
performance measures between people with diabetes mellitus (DM), people with diabetes 
mellitus and peripheral neuropathy (DM+PN), and an age- and BMI- matched group 
without diabetes and without peripheral neuropathy (NoDMPN); b) to determine  the 
relationship between calf muscle structure and composition, measures of muscle 
performance (peak torque, average power) and physical performance (PPT, 6 minute 
walk test, stair power); and c) to determine if the volume of IMAT present is different 
between individual muscles and muscle compartments. We hypothesized that the groups 
with DM and DM+PN would have greater volumes of IMAT in the calf, and similar calf 
muscle volumes compared to the NoDMPN group, and that the DM+PN group would 
display the largest volume of calf IMAT of all 3 groups. Additionally, we hypothesized 
that calf IMAT volume would be inversely correlated with measures of physical 
performance and that the soleus muscle would display more IMAT than the 
gastrocnemius muscle and all other calf compartments across the three groups due to the 
predominance of slow twitch fibers and higher lipid oxidation capacity in the soleus 
muscle. 
Methods and Procedures 
Participants 
  Forty-five subjects participated in this study—11 people with type 2 diabetes 
[5men/6 women; aged 56(9); BMI 35.5(6.4)], 24 people with diabetes and peripheral 
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neuropathy [15 men/9 women; aged 64(13); BMI 32.6(6.3)], and 10 people without 
diabetes and without peripheral neuropathy [4 men/6 women; aged 64(9); BMI 
32.9(4.6)]. The groups were matched for age and BMI.  Participants were recruited from 
the Washington University School of Medicine Diabetes Clinic, Washington University’s 
Volunteers for Health, the Center for Community Based Research, and from diabetes 
clinics in the surrounding St. Louis community.  This study is part of a larger study 
investigating the effect of exercise for people with diabetes and peripheral neuropathy. 
Participant characteristics are listed in Table 1. Participants were excluded if they 
weighed more than 300 pounds (equipment weight limit), had a history of severe foot 
deformity or amputation, any co-morbidity or medications that would interfere with 
exercise (such as severe rheumatoid arthritis, peripheral arterial disease (absent pulses), 
dialysis, or current cancer treatment). Participants provided written informed consent.  
This study was approved by the Human Research Protection Office at Washington 
University in St. Louis.   
 Assessments 
 Peripheral Neuropathy 
  Presence of peripheral neuropathy was determined based on an inability to feel 
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of 
the foot, and on a vibration perception threshold greater than 25V as measured with a 
biothesiometer applied to the plantar surface of the great toe (Maluf et al., 2003 and 
Diamond et al., 1989). 
 Six Minute Walk Test 
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  All participants performed the six minute walk test (ATS Committee on 
Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002) which was 
validated previously in obese adults (Beriault et al., 2009).  The participants walked back 
and forth in a hallway between 2 cones that were placed 100 feet apart.  The participants 
were instructed that the goal was to walk as far as possible in 6 minutes.  Six minute walk 
distance was recorded as total distance walked (in feet). 
 Physical Performance Test (PPT) 
  The modified 9-item PPT was used to assess physical performance in all 
participants.  This test is designed to mimic activities of daily living and the 9-item PPT 
has been shown to correlate well with disability and frailty (Brown et al., 2000, Binder et 
al., 1999, and Brown et al., 2000). The 9-item PPT includes placing a book on a shelf, 
putting a lab coat on and taking it off, picking up a coin from the floor, a 25 foot walk 
down and back at a fast speed, turning in a 360 degree circle, simulated eating, writing a 
sentence, climbing a flight of stairs with 10 steps, and sit to stand 5 times from a low 
chair. Each of the items is scored on a scale of 0-4 based on the time it takes to complete 
the task. Each task is performed twice and the average time is used to determine the 0-4 
score.  A maximum score is indicated by a score of 36. 
 Stair Power Measure 
  Stair power (in watts) was calculated based on the time it took each participant to 
climb a flight of 10 stairs as part of the PPT (average of 2 trials) using the following 
formula: 
 Stair Power = 3.171*Weight(kg)/time(sec) Climb avg*1/.1383*1/.7378  
  Where 3.171=Distance Traveled (m) 
  Climb avg= average time to climb a flight of 10 stairs (sec); 
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  1/.1383=Conversion (kgm/s to ftlbs/s); 
  1/.7378=Conversion (ftlbs/s to Watts) 
Subjects were allowed to touch a handrail for balance, but not for pulling or pushing to 
ascend the stairs. 
 Intermuscular Adipose Tissue (IMAT) 
 Calf intermuscular adipose tissue volumes were quantified using MRI on the right 
leg of each participant.  The MRI scans were performed with the participant in a supine 
position with a Siemens CP extremity coil placed over the right calf muscle.  The MRI 
measurements were performed with a 3.0-Tessla superconducting magnet with a pulse 
sequence of TE=12 milliseconds, TR=1,500 milliseconds, matrix=256x256; both a fat 
saturated and a non fat saturated image were collected (Hilton et al., 2008).  Thirty 
transverse slices were collected beginning at the joint space of the knee and proceeding 
distally.  The slices were 7mm thick with no interslice gap.  Nine consecutive slices were 
selected to calculate muscle and IMAT volumes.  Volumes were quantified using a PC 
workstation and custom Matlab software.  The software uses voxel brightness to 
distinguish between muscle and adipose tissues. The subcutaneous adipose tissue was 
removed from each image by drawing a line along the deep fascial plane surrounding the 
calf muscle so that only the fat within and between the muscles (IMAT) was remaining. 
The software uses edge detection algorithms to assist the user in separating the 
subcutaneous fat from the muscle as well as separating individual muscles and muscle 
compartments.  In the calf, the muscle was divided into 1) the anterior compartment, 2) 
the lateral compartment, 3) the deep compartment, 4) the gastrocnemius muscle, and 5) 
the soleus muscle. Figure 1.   Calf IMAT and calf muscle volumes are reported in cm3.  
An additional variable, IMAT per muscle volume was also used in analysis.   Based on 
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test-retest reliability of 21 subjects, the error in measuring muscle volume is less than 1% 
and less than 2% for measuring fat volumes on average in any muscle or compartment. 
 Ankle Dorsiflexion and Plantarflexion Peak Torque and Power 
  Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque and power 
were assessed using a Biodex Multijoint System 3 Pro isokinetic dynamometer.  The tests 
were performed at angular velocities of 60○/s.  The average power at 60○/s was 
determined by the time-averaged integrated area under the curve at the constant velocity 
of movement in the available range of motion (Hilton et al., 2008).  All participants were 
given 3 practice trials to ensure they were comfortable with the test.  The mean values for 
peak torque and average power were calculated for 3 trials.   
  
Statistical Methods 
  Statistical analyses were performed using Systat for windows, version 13.0.  An 
analysis of variance was used to examine the main and interaction effects of group (DM, 
DM+PN, NoDMPN) and measures of physical performance, calf muscle volume, and 
calf IMAT (gastrocnemius, soleus, anterior compartment, lateral compartment, deep 
compartment).  Post-hoc t-tests were used to examine differences in groups (DM, 
DM+PN, NoDMPN) on the variables of physical performance, calf IMAT, and calf 
muscle volumes as needed based on the results of the ANOVA.  Pearson correlations 
were used to examine the associations between variables. Significance level was set at 
P=0.05. 
 
Results 
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 Group differences were significant for measures of physical performance: six 
minute walk distance (P=0.04), physical performance test (P=0.001) and stair power 
(P=0.04).   Table 3.  The NoDMPN group had a longer six minute walk distance than the 
DM or DM+PN groups. The PPT scores were highest for the NoDMPN group and lowest 
for the DM+PN group.  Stair power values were highest for the NoDMPN group and 
lowest for the DM+PN group. There were no group differences between total calf muscle 
volume, calf IMAT volume,  anterior compartment muscle volume, anterior compartment 
IMAT volume, lateral compartment muscle volume, lateral compartment IMAT volume, 
deep compartment muscle volume, deep compartment IMAT volume, soleus muscle 
volume, soleus IMAT volume, gastrocnemius muscle volume, gastrocnemius IMAT 
volume, and IMAT/Muscle Volume.  Table 2. There were group differences in 
dorsiflexor peak torque and power values with the DM group having higher dorsiflexor 
peak torque and power than the DM+PN and NoDMPN groups (P=0.00), but no group 
differences in plantarflexor peak torque and power (P=0.37).   
 Across all participants, calf IMAT volume was associated with BMI (r=0.31) and 
IMAT volume was associated with poorer physical performance on the 6 minute walk 
test (r=-0.47) and the physical performance test (r=-0.36).  IMAT/Muscle Volume was 
also associated with poor physical performance (PPT r=-0.44, 6MW r=-0.48). Muscle 
volume was not strongly associated with 6 minute walk distance or physical performance 
test score, but was associated with stair power (r= 0.51). Table 4. 
 The gastrocnemius muscle had a higher ratio of IMAT/Muscle volume than any 
other muscle or compartment [0.286(0.37) (gastrocnemius) vs. 0.131(0.13) (soleus) vs. 
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0.154(0.16) (anterior compartment) vs. 0.181 (deep) vs. 0.187 (lateral) P=.005] across all 
participants.    
Discussion 
 This study is the first to examine the impact of IMAT accumulation on specific 
calf muscle compartments and muscle groups and relates it to calf muscle performance 
and individual level physical performance.  In addition, this study shows that people with 
DM and DM+PN have lower physical performance in comparison to a group without DM 
or PN matched for age and BMI. This study is the first to report that IMAT accumulation 
may be muscle and compartment specific in people with diabetes, peripheral neuropathy, 
or obesity. 
 Interestingly, while there were no measurable differences in muscle morphology 
between the 3 groups, there was a difference in measures of physical performance 
between the 3 groups.  We found that the NoDMPN (obese) group had higher levels of 
physical performance than the group with DM and the group with DM+PN.  These 
results could indicate that the pathologies of diabetes and diabetes and neuropathy have a 
greater impact on physical performance than obesity alone.   
 Overall, the inverse correlation between calf IMAT volume and physical 
performance indicates that IMAT accumulation is associated with physical performance 
decline, but it appears that there are other factors, such as the presence of diabetes and/or 
neuropathy that are key mediators of physical performance.  The ratio of IMAT/Muscle 
volume was inversely related to measures of muscle performance across all subjects. The 
ratio of calf IMAT/Muscle volume may be a predictor of physical performance, but the 
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IMAT/Muscle volume does not differ between those with diabetes and diabetes and 
neuropathy compared to a NoDMPN, obese group of subjects.  These results are 
consistent with other reports in the literature and suggest measures other than absolute 
muscle volume or muscle cross-sectional area are needed to completely characterize calf 
muscle composition and muscle performance (Hilton et al., 2008, Park et al., 2006).  
These data are also consistent with reports that people with DM or DM+PN have 
limitations in physical performance and function beyond what is fully explained by 
muscle changes alone (Park et al., 2006, Anderson et al., 1997).  Certainly problems 
secondary to sensory neuropathy can contribute to these deficits in physical performance 
(Cavanagh et al., 1992). 
 We found, contrary to our expectations, that there were no group differences in 
measures of IMAT volumes, or muscle volumes between groups with DM, a group with 
DM+PN, and a NoDMPN group matched for age and BMI.  These results indicate that 
diabetes and peripheral neuropathy were not associated with IMAT accumulation in the 
calf beyond their association with BMI in these groups of subjects.  These results were 
surprising because our previous study indicated that a group with diabetes, peripheral 
neuropathy and obesity had two times the volume of IMAT compared to a non-obese, 
non diabetic, non- neuropathic control group (Hilton et al., 2008).  We expected that the 
presence of diabetes or diabetes and neuropathy in addition to obesity would have an 
additive effect on IMAT volume of the calf muscles.  Our previous study had a small 
sample size (6 in each group) and we reported IMAT volumes that were larger than what 
we report here.  Four of the six subjects with DM+PN in that group were sampled from a 
patient sample with a history of foot ulcers rather than the community at large, so it is 
28 
 
possible that we were capturing a group with more severe involvement of DM and PN 
than what we report here.  
 This is the first study to report that the amount of IMAT/Muscle volume in the 
calf was muscle specific in these pathologies. The gastrocnemius muscle had the largest 
ratio of IMAT/Muscle volume of any of the calf muscles and compartments, which was 
contrary to what we expected.  It is possible that individual muscles are affected by 
IMAT infiltration differently and the gastrocnemius muscle may be preferentially 
affected by IMAT infiltration. We can only speculate that perhaps those muscles with a 
predominance of fast-twitch fibers are affected by IMAT accumulation preferentially or 
sequentially. The plantar flexor muscles are important for ankle stability, walking 
velocity and cadence (Perry et al. 1993).  Furthermore, the gastrocnemius is used more 
for power and burst type activity compared to the soleus muscle which is most active for 
postural control.  Perhaps the gastrocnemius is more affected by IMAT than the soleus 
muscle due to a greater reduction in power activities compared to postural activities in 
these groups. Additional studies are required to determine the underlying mechanisms for 
the IMAT accumulation in the gastrocnemius muscle and its propensity for having 
greater fat infiltration than other calf muscles.  Understanding the muscle specific 
distribution of fat and the underlying mechanisms for fat infiltration may lead to 
enhanced treatment strategies to improve the health of the muscle and individual. For 
example, Marcus et al. (2008) demonstrated that people with type 2 diabetes were able to 
improve performance, decrease fat, and increase lean tissue in the thigh muscles after a 
16 week exercise program that included both aerobic and high-intensity eccentric 
exercise training. Perhaps specific rehabilitation strategies that target the gastrocnemius 
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muscle could alter the fat infiltration and improve deficits in muscle performance and 
physical performance. 
 Of note, the NoDMPN group had an average HbA1c value of 5.8 which is 
indicative of people at risk for developing diabetes (Zhang et al. 2010).  This is consistent 
with other reports in the literature that link IMAT with insulin resistance (Goodpaster et 
al., 2000 and Gallagher et al., 2005) and this could be a potential indicator of those at risk 
for developing diabetes.  Interestingly, the NoDMPN group had higher levels of physical 
performance than the DM or DM+PN groups, so perhaps an intervention targeted at 
minimizing IMAT could diminish risk for developing diabetes and mitigate the 
functional decline that is associated with diabetes and diabetes and peripheral neuropathy. 
 There are limitations that should be considered.  First, we have a relatively small 
sample size. Based on the small effect size between groups, a post-hoc power analysis 
revealed that we would need to collect data on more than 3600 individuals to determine 
group differences in total IMAT in the calf with a power of 0.80 and an alpha level at 
0.05.  Given this power analysis, we believe that total IMAT accumulation in the calf is 
not due to an additive effect of diabetes and diabetes and neuropathy in this particular 
sampling of subjects. The magnitude and impact of IMAT accumulation in specific calf 
muscles or compartments in people with severe diabetes and peripheral neuropathy 
requires additional investigation. This study is also limited in that we do not have a 
measure of activity level for each participant, so it is possible that our groups could be 
different from each other in levels of activity.  Since the group with DM+PN was 
originally recruited for an exercise study, it is possible that we have a selection bias 
towards people with DM+PN who are higher functioning. In addition, this group only 
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had 2 people with a history of plantar foot ulcer, so we do not believe these results are 
generalizable to people with more severe complications and longer durations of diabetes 
and peripheral neuropathy.  Lastly, the correlations between the different variables within 
and between groups only indicate association and cannot determine cause and effect. 
 In conclusion, this study found that increased calf IMAT was associated with 
poorer physical performance and IMAT may target specific muscles and muscle 
compartments differently, specifically; the gastrocnemius muscle was more affected than 
other muscles of the calf.  The groups with DM and DM+PN had lower measures of 
physical performance than the NoDMPN group, suggesting that more severe impairment 
in metabolic pathology along with IMAT accumulation impacts physical performance.   
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 Table 1. Subject Demographics by Group. Values are means(SD). 
Group N Gender (M/F) 
Age 
(years) 
BMI 
(kg/m2) 
Weight 
(lbs) 
Diabetes Medication 
(oral only/insulin 
&oral) 
HbA1c DM Duration (years) 
DM 11 5/6 56(9) 35.5(6.4) 226(33) 6/5 8.1(2.2) 8.1(6.9) 
DM+PN 24 15/9 64(13) 32.6(6.3) 217(45) 13/11 7.1(1.3) 12.9(9.0) 
NoDMPN 10 4/6 64(9) 32.9(4.6) 213(41) NA 5.8(0.2) NA 
NA: Not Applicable 
 
3
1
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Table 2. ANOVA results: muscle morphology measures; all values are means(SD) in 
cm3. 
 DM DM+PN No DMPN P-Values 
Muscle Volume  434(72) 407(88) 404(90) 0.65 
IMAT Volume 65(36) 70(40) 67(54) 0.94 
Anterior 
Compartment 
Muscle Volume  
69(15) 65(14) 62(9) 0.57 
Anterior 
Compartment 
IMAT Volume  
10(11) 9(5) 7(5) 0.53 
Lateral 
Compartment 
Muscle Volume  
38(9) 37(11) 36(10) 0.85 
Lateral 
Compartment 
IMAT Volume  
5(3) 7(4) 6(5) 0.62 
Deep 
Compartment 
Muscle Volume  
54(13) 60(12) 51(15) 0.15 
Deep 
Compartment 
IMAT Volume 
8(4) 11(5) 9(6) 0.23 
Soleus Muscle 
Volume  130(26) 118(32) 127(28) 0.46 
Soleus IMAT 
Volume  14(8) 15(10) 14(14) 0.97 
Gastrocnemius 
Muscle Volume  142(27) 122(40) 128(31) 0.35 
Gastrocnemius 
IMAT Volume  27(15) 28(21) 31(28) 0.90 
IMAT/Muscle 
Volume  0.158(0.11) 0.193(0.16) 0.144(0.07) 0.58 
Anterior Compartment: comprised of tibialis anterior, extensor digitorum longus, and 
extensor hallucis longus muscles 
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Lateral Compartment: comprised of peroneus longus and brevis muscles 
Deep Compartment: comprised of the tibialis posterior, flexor digitorum longus and 
flexor hallucis longus muscles 
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Table 3. ANOVA results: physical performance measures. Values are means(SD) 
 DM DM+PN No DMPN P-Values 
DFPT (Nm) 15.3(7.5)a 4.5(5.3) 5.2(4.3) 0.00 
DFPOW (W) 9.8(6.6)a 2.2(3.2) 2.3(2.4) 0.00 
PFPT (Nm) 48.1(13.0) 51.4(16.5) 58.0(18.6) 0.37 
PFPOW (W) 38.7(10.9) 41.9(18.1) 45.9(15.1) 0.38 
6MW (feet) 1508(262) 1396(323) 1681(159)a 0.04 
PPT 31(2.4) 28(4.0) 34(1.5) 0.001* 
Stair Power (W) 671(163) 601(226) 808(327) 0.04* 
* indicates all 3 groups are different 
a
 indicates that group is different from other 2 groups 
DFPT=dorsiflexor peak torque 
DFPOW=dorsiflexor power 
PFPT=plantarflexor peak torque 
PFPOW=plantarflexor power 
6MW=six minute walk distance 
PPT=physical performance test (9-item)
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Table 4.  Correlation Matrix. 
 
IMAT 
vol 
6MW PPT StairPOW MuscleVol IMAT/MusVol 
BMI 0.31* -0.18 0.01 0.21 0.49* 0.08 
IMAT vol  -0.47* -0.36* -0.18 -0.32* 0.93* 
6MW   0.79* 0.58* 0.25 -0.48* 
PPT    0.60* 0.24 -0.44* 
Stair Pow     0.51* -0.30* 
Muscle vol      -0.35* 
* indicates significance (P<0.05) 
IMAT=intermuscular adipose tissue volume 
6MW=six minute walk distance  
PPT=physical performance test (9-item) 
Stair Pow=stair power  
Muscle Vol=calf muscle volume  
IMAT/MusVol=ratio of IMAT/Muscle Volume in the calf 
  
 
Figure 1. A) MRI image of calf with bone removed. B) Subcutaneous adipose tissue removed.  
C) Calf divided into 5 compartments (anterior, lateral, deep, gastrocnemius, soleus) 
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Chapter 3 
Lower Physical Activity is Associated with Higher Intermuscular Adipose Tissue in 
People with Type 2 Diabetes and Peripheral Neuropathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Tuttle LJ, Sinacore DR, Cade WT, Mueller MJ, Lower Physical Activity 
is Associated with Higher Intermuscular Adipose Tissue in People with Type 2 Diabetes 
and Peripheral Neuropathy, Physical Therapy, in press, with permission of the American 
Physical Therapy Association. This material is copyrighted, and any further reproduction 
or distribution requires written permission from APTA.  This paper is not in its final 
edited form. 
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ABSTRACT 
BACKGROUND.  Increased lipid accumulation in skeletal muscle has been linked to 
insulin resistance, impaired muscle performance, and impaired physical function.  It is 
unclear if physical activity is associated with lipid content in skeletal muscle, muscle 
performance, or overall physical function. 
OBJECTIVE. To characterize physical activity levels (average daily step count) in a 
sample with diabetes and peripheral neuropathy and to determine the relationship 
between step count, intermuscular adipose tissue volume (IMAT), muscle performance 
(peak torque, power), and physical function.   
DESIGN. 22 people with diabetes and peripheral neuropathy [15 men/7 women; aged 
64.5(12.7); BMI 33.2(6.4)] participated.  Average daily step count, HbA1c, modified 9-
item Physical Performance Test, 6 minute walk distance, calf intermuscular adipose 
tissue volume (via MRI), and isokinetic dynamometry of the ankle muscles were 
measured. 
RESULTS. Average daily step count was 7754(4678) steps/day, with a range of 3088 to 
20079 steps/day.  There were 5 subjects with an average daily step count greater than 
10,000. Average IMAT volume was 84(88)cm3. Greater average daily step count was 
associated with younger age (r=-0.39, P<0.05) and with lower IMAT volume in the calf, 
(-0.44, P<0.05). Lower IMAT volume was associated with greater muscle performance 
(r=-0.45) and physical function (r=-0.43- -0.48).   
CONCLUSIONS.  Average daily step count was inversely related to IMAT and IMAT 
was inversely related to muscle performance and overall physical function. In addition 
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we found that people with diabetes, peripheral neuropathy, and without severe foot 
deformity appear to be able to take a high number of steps per day. 
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 Diabetes mellitus is a chronic disease that affects almost 24 million people, with 
60-70% developing nervous system impairments, including peripheral neuropathy.1  
Increased physical activity has been shown to decrease pain and improve balance 
including in people with diabetes and peripheral neuropathy.2  Improved physical activity 
is particularly important for people with diabetes, not only for improved glucose control 
and cardiovascular fitness, but also because people with diabetes are two times more 
likely to have limitations in physical mobility, particularly in the presence of peripheral 
neuropathy.3  The mechanisms for physical mobility limitations in diabetes are unclear, 
but previous work has demonstrated that people with diabetes, peripheral neuropathy and 
obesity have an increased amount of adipose tissue (i.e. fat)  in the muscles of the lower 
extremity that is not noted in their peers and this increased intermuscular adipose tissue is 
associated with poor physical functional status.4  Intermuscular adipose tissue (IMAT) is 
defined as the visible extra-cellular adipose tissue that is located beneath the muscle 
fascia and between and within muscle groups.5 The mechanism by which IMAT 
potentially impairs physical function is unclear, but decreased muscle strength and power 
has been associated with an increased amount of IMAT in the calf and thigh muscles of 
people with diabetes and peripheral neuropathy thereby suggesting increased IMAT as a 
mechanism for impaired physical function.4,6 IMAT has been linked to immobilization in 
healthy young adults7 and has been shown to be reduced with exercise in a population 
with diabetes and without peripheral neuropathy8 indicating that physical activity may be 
a potent modifier of IMAT content in skeletal muscle.  IMAT has also been shown to be 
higher in the affected limb in people with chronic stroke9 and spinal cord injury10 and in 
rotator cuff injury with nerve involvement11 indicating that nerve dysfunction (such as 
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peripheral neuropathy) could impact IMAT. In addition, IMAT has been associated with 
insulin resistance,12 suggesting that IMAT may contribute to or worsen the  metabolic 
impairments of skeletal muscle that accompany diabetes.  It is therefore important to 
determine if IMAT is influenced by physical activity, specifically walking activity and if 
so, if increases in physical activity are associated with greater muscle performance, 
glucose control and physical function in people with DM and PN.  
 The purpose of this study was to characterize activity levels (average daily step 
count) in people with diabetes and peripheral neuropathy and to determine the 
relationship between activity level and IMAT volume in the calf, calf muscle volume, 
muscle performance, physical function, and glucose control. The American Diabetes 
Association recommends that people take 10,000 steps per day,13 but we hypothesized 
that people with diabetes and peripheral neuropathy would take around 5,000 steps per 
day based on prior observations and reports.14-16  We hypothesized that higher average 
daily step count would be associated with lower IMAT volume, larger muscle volume, 
improved glucose control (lower HbA1c levels), higher muscle performance, and higher 
physical function. 
METHOD 
Participants 
  Twenty-two subjects with type 2 diabetes and peripheral neuropathy [15 men/7 
women; aged 64.5(12.7); BMI 33.2(6.4)] were recruited for this study as part of a larger 
study involving exercise for people with diabetes and peripheral neuropathy from the 
Washington University School of Medicine Diabetes Clinic and from diabetes clinics in 
the surrounding St. Louis area. Participants were excluded if they weighed more than 300 
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pounds (equipment weight limit), had a history of severe foot deformity or amputation, 
any co-morbidity or medications that would interfere with exercise (such as severe 
rheumatoid arthritis, peripheral arterial disease (absent pulses), dialysis, or current cancer 
treatment).  Participants were excluded if they had a current foot ulcer; 2 of the 22 
participants had a history of a previous foot ulcer that had been healed for at least 6 
months. Participants provided written informed consent.  This study was approved by the 
Human Research Protection Office at Washington University in St. Louis.   
 Assessments 
 Peripheral Neuropathy 
  Presence of peripheral neuropathy was determined based on an inability to feel 
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of 
the foot and based on a vibration perception threshold of greater than 25 volts as 
measured with a biothesiometer.16,17 
 Activity Monitoring 
  For the purposes of this study, activity level refers specifically to average daily 
step count as recorded by a StepWatch activity monitor.* Participants were given an 
activity monitor and were instructed to wear the monitor around their ankle during all 
waking hours.  The participants were given the monitor for at least 9 consecutive days 
calculating an average of 7 days.  The first and last days of wear were deleted because a 
full 24 hours would not be recorded.  For a day to be included, the monitor had to be 
worn for at least 8 hours, and at least 1 weekend day was included in the 7 day average.  
The device records strides per day and steps per day were calculated by multiplying 
                                                           
*
 Orthocare Innovations, 840 Research Parkway, Suite 200,Oklahoma City, OK 73104. 
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strides by 2 (1 stride equals 2 steps).  Results of validity tests performed in our laboratory 
indicate a mean absolute error of 1.1% (SD, 3.1%) for healthy obese subjects and 1.8% 
(SD, 2.4%) for subjects with diabetes mellitus and peripheral neuropathy.16 
 Six Minute Walk Test 
  All participants performed the six minute walk test18 as a measure of physical 
function and walking endurance which was validated previously in obese adults.19  The 
participants walked back and forth in a hallway between 2 cones that were placed 100 
feet apart.  The participants were told that the goal was to walk as far as possible in 6 
minutes; the test was not repeated.  Six minute walk distance was recorded as total 
distance walked in feet. 
 Physical Performance Test (PPT) 
  The modified 9-item PPT was used to assess physical function in all participants.  
This test is designed to mimic activities of daily living and the 9-item PPT has been 
shown to correlate well with disability and frailty.20-22  Each of the items is scored on a 
scale of 0-4 based on the time it takes to complete the task. Each task is performed twice 
and the average time is used to determine the 0-4 score.  A maximum score is indicated 
by a score of 36. 
 Intermuscular Adipose Tissue (IMAT) 
  Intermuscular adipose tissue volumes were quantified using MRI on the right leg 
of each participant using previously established methods.4    The MRI scans were 
performed with the participant in a supine position with a Siemens CP extremity coil 
placed over the right calf muscle.  The MRI measurements were performed with a 3.0-T 
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superconducting MRI instrument† with a pulse sequence of TE=12 milliseconds, 
TR=1,500 milliseconds, matrix=256x256.  Thirty transverse slices were collected 
beginning at the joint space of the knee and proceeding distally.  The slices were 7mm 
thick with no interslice gap with voxel size of 0.7x0.7x7mm.  The fifteen center 
consecutive slices were selected to calculate muscle and IMAT volumes.  Volumes were 
quantified using a PC workstation and Analyze Direct software version 9.0‡ which uses 
voxel brightness to distinguish between muscle and adipose tissues.5 The subcutaneous 
adipose tissue was removed from each image by drawing a line along the deep fascial 
plane surrounding the calf muscle so that only the fat within and between the muscles 
(IMAT) was remaining. On a subset of 10 participants, intraclass correlation coefficient 
(2,1) values of the same scan by the same observer averaged 0.98 when scans were 
measured at least 7 days apart. 
 Ankle Dorsiflexion and Plantarflexion Peak Torque and Power 
  Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque and power 
as measures of muscle performance were assessed using a Biodex Multijoint System 3 
Pro isokinetic dynamometer.§  The tests were performed at angular velocities of 60○/s.  
The average power at 60○/s was determined by the time-averaged integrated area under 
the curve at the constant velocity of movement in the available ankle joint range of 
motion.4  All participants were given 3 practice trials to ensure they were comfortable 
                                                           
†
 Siemens Corp, Citicorp Center, 153 E. 53rd St., New York, NY 10022. 
‡‡
 Mayo Clinic, 200 First St. SW, Rochester, MN 55905. 
§
 Biodex Medical Systems, 20 Ramsay Road, Shirley, NY 11967. 
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with the test.  The mean values for peak torque and average power were calculated for 3 
trials.   
Data Analysis 
  Statistical analyses were performed using Systat for windows, version 13.0. ** 
Pearson correlation coefficients were used to determine association between variables. 
Multiple regression analysis was performed with average step count as the dependent 
variable and IMAT volume, age, BMI, HbA1c, duration of diabetes, muscle performance 
(dorsiflexion and plantarflexion peak torque and power) and physical performance (six 
minute walk distance and physical performance test score) as the independent variables.  
Statistical significance was set at P<0.05.  Post hoc, the 22 participants were divided into 
3 groups based on step count in an effort to determine if there was something different 
between people who were taking more steps than the group mean (greater than 8000 steps 
per day), those who were in our expected range of step count (5000-8000 steps per day), 
and those who were below the expected step count (less than 5000 steps per day). A one-
way ANOVA was performed with age as a covariate to determine differences in IMAT 
volumes that were due to group differences in activity level. ANOVAs were also 
performed to determine differences in IMAT volume, muscle volume, muscle 
performance, PPT and 6 minute walk distance based on group differences in activity level 
(Table 1). Statistical significance was set at P<0.05.   
  
 Results 
                                                           
**
 Systat Software, Inc., 225 W Washington St., Suite 425, Chicago, IL 60606. 
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  Average daily step count in these 22 participants with diabetes and peripheral 
neuropathy ranged from 3088 steps per day to 20079 steps per day with an average of 
7754(4678) steps per day.  Participant characteristics are listed in Table 1. In order to 
characterize the people who were more active and those who were less active, the 22 
participants were categorized  into 3 groups based on average step count (less than 5000 
steps/day, 5000-8000 steps/day, and greater than 8000 steps per day) (Table 1) .  The 
group that was taking less than 5000 steps/day had 3 times the volume of IMAT in their 
calf muscles compared to the groups that were taking 5000-8000 steps per day and  
greater than 8000 steps per day (157(127) cm3 vs. 53(27) cm3 vs. 42(22) cm3 ;  P<0.05).  
However, the more active group also was younger than the other 2 groups (Table 1) 
therefore, a one-way ANCOVA also was performed with IMAT volume as the dependent 
variable, step count as the independent variable and age as a covariate.  Results were 
unchanged and IMAT volumes remained significantly different (P=0.03) between the 
groups.     
  A multiple regression analysis was used to determine the variance in average step 
count accounted for by IMAT volume, age, BMI, HbA1c, diabetes duration, muscle 
performance, and physical function (Table 2).  IMAT accounted for 19% of the variance 
in average step count (P=0.04).  The other independent variables did not account for a 
significant portion of the variance in IMAT in this sample (P>0.05).  
  Activity as indicated by average step count was associated with age (r=-0.39) and 
with IMAT volume (r=-0.44), but average step count was not associated with glucose 
control (as indicated by HbA1c), muscle performance, muscle volume, or physical 
function (P>0.05) (Table 3).  IMAT volume was associated with select indicators of 
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muscle performance (plantarflexion peak torque r=-0.45, P=0.03) and physical function 
(PPT r=-0.43 P=0.04; 6MW r=-0.48 P=0.02) in addition to an association with average 
step count (r=-0.44 P=0.04).   
Discussion 
 This study is the first to demonstrate an inverse relationship between physical 
activity levels and intermuscular adipose tissue (IMAT) volume in calf muscle in people 
with diabetes and peripheral neuropathy.  We have also demonstrated a significant 
relationship between increased IMAT volume and lower muscle performance and 
physical function.  This finding is in agreement with previous investigators who found 
that increased IMAT was associated with lower muscle performance4,6,12 suggesting that 
IMAT may be a potential pathway for intervention to attenuate the impairments 
associated with diabetes and peripheral neuropathy.    However, these data provide only 
an association between these variables and do not imply causation.  More studies are 
needed to elucidate the role of IMAT in these processes.  In addition, these findings lead 
us to question whether increasing physical activity could decrease IMAT volume and be 
a way to improve physical function in people with DM and PN.  IMAT has also been 
linked to insulin resistance23-26 in people with metabolic syndrome as well as frank 
diabetes.  The exact relationship between IMAT and insulin resistance is not yet 
understood, but there is some evidence that weight loss27 and exercise28-30 can decrease 
the amount of IMAT and improve insulin sensitivity.  It is unknown whether people with 
diabetes and peripheral neuropathy demonstrate these same effects on IMAT in response 
to exercise and weight loss. 
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 We hypothesized that higher average daily step count would be associated with 
less IMAT volume, larger muscle volume, improved glucose control, higher muscle 
performance, and higher physical function.  This study showed that average daily step 
count is inversely correlated with IMAT volume, but step count was not correlated with 
glycemic control, muscle volume, muscle performance or measures of physical function.  
IMAT volume was inversely correlated with muscle performance (plantarflexor peak 
torque) and with measures of physical function (PPT score and 6 minute walk distance).  
These findings suggest that activity could be a modifiable factor that has the potential to 
impact muscle morphology (IMAT volume) and therefore improve physical function.  In 
fact, the people who were the least active actually had three times the volume of IMAT in 
the calf as the people who were most active, on average (Table 1).  Physical activity has 
been associated with IMAT in a young healthy population,7 but this is the first study 
reporting that activity is associated with IMAT volume in a population with diabetes and 
peripheral neuropathy.  These results provide evidence for a potential way to impact not 
only the metabolic disturbance of diabetes but to also improve the functional deficits that 
have been shown to occur in people with diabetes and peripheral neuropathy. Indeed, 
Marcus et al.8 demonstrated that people with type 2 diabetes were able to improve 
performance, decrease fat, and increase lean tissue in the thigh after a 16 week exercise 
program that included both aerobic and eccentric exercise training. Additional studies are 
needed to determine if more intensive interventions targeted to increase activity or 
muscle strength can improve muscle and physical function in people with diabetes and 
peripheral neuropathy. While the relationship between average step count and IMAT 
volume was significant, there was also great variability in IMAT volume, particularly in 
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people with a lower step count.  As noted in our multiple regression analysis, IMAT only 
accounted for 19% of the variation in step count and there are many other factors that 
could be contributing to the variability seen in both IMAT and step count. More studies 
are needed to be able to determine the variety of factors that impact IMAT volume. 
 In our previous work4 we found that people with diabetes, peripheral neuropathy 
and obesity had a greater amount of IMAT volume in their calf muscles than their age-
matched peers who did not have diabetes or peripheral neuropathy and who were not 
obese. In our previous study, IMAT volume was related to muscle performance and 
function. However, we did not have measures of activity level in our previous study. The 
findings in this study that IMAT volume was associated with muscle performance and 
function are consistent with our previous results and expand upon this previous work to 
include activity level as a factor that may influence muscle performance and physical 
function. The results suggest that activity is associated with muscle morphology and 
could potentially be a way to improve the impaired physical function that accompanies 
chronic diabetes.   
 Based on previous studies, we hypothesized that people with diabetes and 
peripheral neuropathy would be taking around 5,000 steps per day.15,16  We hypothesized 
this because generally, the expectation is that people with diabetes and peripheral 
neuropathy are less active than their peers, however, the group for this study had an 
average daily step count of 7919 and there were 5 people with diabetes and peripheral 
neuropathy who were taking more than 10,000 steps per day.  The average step counts in 
this study are consistent with those from Maluf et al16; however they are significantly 
higher than those reported by Armstrong et al.15 Because we were recruiting for an 
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exercise study, our sample may be biased toward those who have high activity and 
limited our ability to recruit participants who are less active.  
 Surprisingly, HbA1C levels were not associated with activity. This is in conflict 
with other reports in the literature that indicate that exercise and increased physical 
activity will improve glucose control.31  There are several potential explanations for this.  
First, the participants in this study were not participating in a regular exercise program; 
the activity measure is a measure of regular daily walking activity.  Intensity of exercise 
is a key factor in maintaining blood glucose control, and perhaps normal daily walking, 
regardless of total number of steps, does not reach an intensity level that is consistent 
with regulating blood glucose over the previous 3 to 4 month time period that HbA1c 
indicates.  Also, one limitation of this study is that we do not have any information on 
diet in these participants and it is possible that dietary habits contributed more to overall 
HbA1c values than low intensity physical activity in this particular sample.  It is also 
possible that some of the participants in this study were not compliant in taking their 
daily medication, which could also adversely affect HbA1c values.   
 While this study provides important information about the role of activity in 
people with diabetes and peripheral neuropathy, there are limitations that should be 
considered.  First, the participants in this study were all interested in participating in an 
exercise study, so it is possible that our sample is biased towards those who tend to be 
more active.  It is unclear whether our results are generalizable to people who are taking 
less than 3000 steps/day.  In addition, we excluded people who had a current foot ulcer, 
peripheral arterial disease, severe foot deformity or amputation, or who weighed greater 
than 300 pounds.  Our results should not be generalized to these populations.  There is 
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evidence that walking capacity and performance decrease in the presence of severe foot 
deformity or amputation.32 Additional research is needed to clarify the contraindications 
and safety precautions for a walking program or weight bearing exercise program given 
various levels of foot deformities and impairments. Also, based on these data, we can 
only say that step count and IMAT volumes are associated, but we cannot specify 
causation.  
 In conclusion, physical activity is associated with IMAT volume and IMAT 
volume is related to muscle performance and overall physical function.  In addition we 
found that people with diabetes, peripheral neuropathy, and without severe foot deformity 
appear to be able to take a high number of steps per day.  More evidence is needed to 
determine if an exercise program designed to increase step count will decrease the 
amount of IMAT volume and enhance muscle performance and physical function.  
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Table 1. Values are mean (SD) unless otherwise indicated 
 
P values are from the ANOVA results between the 3 different groups based on activity level. 
PPT=modified 9-item physical performance test score; 6MW=six minute walk distance; IMAT=intermuscular adipose tissue volume 
in the calf; PFPT=plantarflexor peak torque 
 
* indicates difference from other 2 groups based on post hoc t-tests from ANOVA results (P<0.05) 
# indicates all 3 groups are different from each other based on post hoc t-tests from ANOVA results (P<0.05) 
 
Step 
Count 
(steps/day) 
N Gender (M/F) 
Age 
(yrs) BMI HbA1c 
Duration 
of 
Diabetes 
(yrs) 
Vibration 
Perception 
Threshold 
(Volts) 
Average 
Step Count 
(steps/day) 
IMAT 
(cm3) 
Muscle 
Volume 
(cm3) 
PPT 6MW (feet) 
PFPT 
(ft lbs) 
<5000 7 4/3 68(14) 35.5(6.7) 7.0(1.2) 11(6) 42(10) 3995(624) 157(127)* 735(206) 26(5) 1147(300)* 33.3(12.5) 
5000-8000 8 6/2 69(10) 30.5(6.1) 6.9(0.4) 11(9) 39(11) 6310(1032) 53(27) 811(253) 30(2) 1564(244) 42.7(10.5) 
>8000 7 5/2 55(11)* 33.9(6.2) 7.4(2.2) 11(7) 40(11) 13162(4645) 44(22) 880(66) 29(3) 1471(346) 44.1(7.9) 
P values   0.05 0.30 0.78 0.98 0.86 <0.00# 0.02 0.40 0.07 0.04 0.13 
Full 
Range 22 15/7 65(13) 33.2(6.4) 7.1(1.4) 11(7) 40(10) 7754(4678) 84(88) 809(196) 28(4) 1402(336) 40.1(11.1) 
5
4
 
55 
 
 
Table 2—multiple regression analysis results for Step Count as dependent variable. 
 R R Square R Square Change Sig. F Change 
IMAT 0.44 0.19 0.19 0.04 
Age 0.51 0.26 0.07 0.19 
BMI 0.53 0.28 0.02 0.51 
HbA1c 0.61 0.38 0.10 0.13 
DM Duration 0.61 0.38 0.00 0.84 
Muscle Performance 0.63 0.39 0.01 0.90 
Physical Performance 0.74 0.55 0.16 0.17 
IMAT=Intermuscular adipose tissue; Muscle Performance=dorsiflexion and 
plantarflexion peak torque and power; Physical Performance=6 minute walk and physical 
performance test scores 
  
Table 3—univariate correlation matrix 
 Steps MVol HbA1c PPT 6MW IMAT DFPT DFPOW PFPT PFPOW DM DUR VPT 
Age -0.39* -0.46* -0.54* -0.15 -0.22 0.31 -0.20 -0.12 -0.23 -0.21 -0.04 0.36 
Steps  0.23 -0.12 0.27 0.10 -0.44* 0.05 -0.02 0.19 0.18 -0.09 -0.03 
MVol   0.35 0.09 0.17 -0.45* 0.69* 0.65* 0.36 0.12 -0.02 -0.03 
HbA1c    -0.18 0.04 -0.11 0.20 0.15 0.12 0.05 0.22 -0.39* 
PPT     0.75* -0.43* -0.03 -0.08 0.55* 0.43* -0.36 -0.08 
6MW      -0.48* 0.08 0.03 0.47* 0.48* -0.27 -0.06 
IMAT       -0.06 -0.02 -0.45* -0.29 -0.05 -0.16 
DFPT        0.97* 0.37 0.14 0.03 0.03 
DFPOW         0.28 0.02 0.00 0.10 
PFPT          0.82* -0.35 -0.02 
PFPOW           -0.43* -0.08 
DM DUR            -0.01 
*indicates significance P<0.05 
Steps=average daily step count; MVol=muscle volume in the calf; PPT=modified 9-item physical performance test score; 6MW=six 
minute walk distance; IMAT=intermuscular adipose tissue volume in the calf; DFPT=dorsiflexor peak torque; DFPOW=dorsiflexor 
power; PFPT=plantarflexor peak torque; PFPOW=plantarflexor power; DM DUR=duration of time with diabetes; VPT=vibration 
perception threshold (measure of neuropathy) 
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ABSTRACT 
OBJECTIVE—  The purpose of this study was to determine the effect of a 12 week 
progressive walking exercise program on physical performance (Physical Performance 
Test, 6 minute walk test), calf muscle performance (dorsiflexor and plantarflexor peak 
torque), and calf muscle structure and composition (intermuscular adipose tissue [IMAT], 
muscle volume) in people with diabetes and peripheral neuropathy (DM+PN) who 
complete the 12 weeks of training (EX group) and compare these outcomes to a group of 
people with DM+PN who do not complete the training (CON group). 
RESEARCH DESIGN AND METHODS— Ten subjects in the EX group were 
compared to 10 subjects in the CON group, all with diabetes and peripheral neuropathy 
[14 men/6 women; aged 66(12); BMI 36(7)]. Modified 9-item Physical Performance 
Test, 6 minute walk distance, isokinetic dynamometry of the ankle muscles, and calf 
IMAT volume (via MRI) were measured. 
RESULTS— Following the 12 week exercise intervention, the EX group had a 
significant increase in the six minute walk distance [1266(263) to 1352(286) feet] 
compared to the CON group [1409 (293) to 1398 (234) feet] (P<0.05).  There were no 
other significant differences between the groups. 
CONCLUSIONS—People with diabetes and peripheral neuropathy are able to tolerate a 
progressive walking and exercise program and increase six minute walk distance. They 
showed no significant calf muscle changes with this mild exercise intensity. 
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 The benefits of exercise to help control diabetes mellitus (DM) and reduce 
subsequent complications are well known and accepted (1).    In addition to improved 
DM control and lower mortality rates, walking and increased activity appears to improve 
complications such as neuropathic pain from peripheral neuropathy (PN) (2). The 
evidence of the benefits of exercise for people with DM has led the American Diabetes 
Association (ADA) and the American College of Sports Medicine (ACSM) (1) to 
recommend that adults with DM participate in at least 30 minutes per day of moderate-
intensity physical activity, but the effects of this exercise program is not well known in 
people with DM+PN.   
 People with DM+PN have reduced ankle muscle strength and volume with plantar flexor 
peak torque values in people with DM+PN being about 50% of that in people without DM+PN 
(3-5).  Calf muscle strength is decreased and declines more rapidly in individuals with DM + PN 
compared to muscular changes associated with normal aging (5).  The lower extremity 
musculature of individuals with DM+PN also demonstrates substantial intermuscular adipose 
tissue (IMAT) infiltration and muscle atrophy as measured by magnetic resonance imaging 
compared to people without DM+PN (6). Intermuscular adipose tissue (IMAT) is defined as the 
visible extra-cellular adipose tissue that is located beneath the muscle fascia and between and 
within muscle groups (7). It has been demonstrated that IMAT in the thigh is sensitive to changes 
in activity and exercise programs in an older population (7) as well as in a group with DM (8), but 
it is unclear whether an exercise program can impact IMAT or lean muscle volume in the calf of 
people with DM+PN. 
 Although people with DM+PN clearly have lower extremity impairments, little evidence 
exists to determine if these impairments can improve with exercise. The Centers for Disease 
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Control and Prevention reports adults with DM compared to those without have an odds ratio of 
2.0 for having mobility limitations.  The incidence of impaired mobility increases with peripheral 
artery disease and/or peripheral neuropathy; subjects with DM and lower extremity diseases had an 
almost 3-fold increase in risk of impaired mobility compared to those having neither (9).    The 
most frequently reported mobility limitations were related to patients’ inability to walk a quarter 
mile and to walk up 10 steps without resting (9).  The ADA and ACSM have recently reported that 
individuals with peripheral neuropathy and without acute ulceration may participate in moderate 
weight-bearing exercise (1) and previous studies (10) have indicated that people with DM+PN 
were able to participate in a low-intensity walking program without increasing risk of ulceration.  
It is unclear exactly what “moderate weight-bearing exercise” entails and how that might affect 
physical function and strength in people with DM+PN. A previous study investigating the effects 
of exercise in people with DM+PN  reported  no strength changes with a low-intensity exercise 
program (11) and a Cochrane review of the literature concluded that there is inadequate evidence 
to evaluate the effect of strengthening exercise for people with DM+PN (12).  
 The purpose of this study was to determine the effect of a 12 week progressive walking 
exercise program on physical performance (Physical Performance Test, 6 minute walk test), calf 
muscle performance (dorsiflexor and plantarflexor peak torque), and calf muscle structure and 
composition (IMAT, muscle volume) in people with DM+PN who participated in the 12 weeks of 
training (EX group) and compare these outcomes to a group of people with DM+PN who do not 
complete the training (CON group). We hypothesized that 1) the EX group would display 
improved physical performance compared to the CON group 2) the EX group would display 
increased dorsiflexor and plantarflexor peak torque after a progressive exercise program compared 
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to the CON group and 3) the EX group would display decreased IMAT in calf muscles and 
increased calf muscle volume after a progressive exercise program compared to the CON group. 
Research Design and Methods 
  A total of 20 people with DM + PN (14 men/6 women; aged 66+12; BMI 36+7) 
are reported in this study which was a portion of a larger randomized controlled clinical 
trial involving exercise for people with DM+PN.  The primary reason for studying this 
subgroup was to use MRI to investigate muscle changes secondary to the progressive 
exercise program. Participant characteristics by group are listed in Table 1. Participants 
were excluded if they 1) weighed more than 300 pounds (equipment weight limit), 2) had 
a history of severe foot deformity or amputation, 3) had any co-morbidity or medications 
that would interfere with exercise, 4) did not have peripheral neuropathy, 5) were 
currently exercising regularly, 6) had a step count less than 2,000 steps per day or greater 
than 10,000 steps per day on average (screened with the StepWatch accelerometer over 7 
days), 7) or if they had a current foot ulcer; none of the participants in this study had a 
history of foot ulcer.  Participants provided written informed consent.  This study was 
approved by the Human Research Protection Office at Washington University in St. 
Louis.   
 Peripheral Neuropathy 
  Presence of peripheral neuropathy was determined based on an inability to feel 
the 5.07 Semmes-Weinstein monofilament on at least one point on the plantar surface of 
the foot and based on a vibration perception threshold of greater than 25V as measured 
with a biothesiometer (13,14). 
 Six Minute Walk Test 
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  All participants performed the six minute walk test (15) as a measure of physical 
function and walking endurance. The test has been validated in obese adults (16).  The 
participants walked back and forth in a hallway between 2 cones that were placed 100 
feet apart.  The participants were told that the goal was to walk as far as possible in 6 
minutes.  Six minute walk distance was recorded as total distance walked in feet. 
 Physical Performance Test (PPT) 
  The modified 9-item PPT was used to assess physical function in all participants.  
This test is designed to mimic activities of daily living and includes items such as stair 
climbing, and coming sit-to-stand. The 9-item PPT has been shown to correlate well with 
disability and frailty (17).  Each of the items is scored on a scale of 0-4 based on the time 
it takes to complete the task. Each task is performed twice and the average time is used to 
determine the 0-4 score.  A maximum score is indicated by a score of 36. 
 Intermuscular Adipose Tissue (IMAT) and Muscle Volumes 
 Intermuscular adipose tissue and lean muscle volumes were quantified using MRI 
on the right leg of each participant.  The MRI scans were performed with the participant 
in a supine position with a Siemens CP extremity coil placed over the right calf muscle.  
The MRI measurements were performed with a 3.0-Tessla superconducting MRI 
instrument with a pulse sequence of TE=12 milliseconds, TR=1,500 milliseconds, 
matrix=256x256; both a fat saturated and a non fat saturated image were collected (6).  
Thirty transverse slices were collected beginning at the joint space of the knee and 
proceeding distally.  The slices were 7mm thick with no interslice gap.  Nine consecutive 
slices were selected to calculate muscle and IMAT volumes.  Volumes were quantified 
using a PC workstation and custom Matlab software.  The software uses voxel brightness 
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to distinguish between muscle and adipose tissues. The subcutaneous adipose tissue was 
removed from each image by drawing a line along the deep fascial plane surrounding the 
calf muscle so that only the fat within and between the muscles (IMAT) was remaining. 
The software uses edge detection algorithms to assist the user in separating the 
subcutaneous fat from the muscle as well as separating individual muscles and muscle 
compartments.  IMAT and muscle volumes are reported in cm3.  Based on test-retest 
reliability of 21 subjects, the error in measuring muscle volume is less than 1% and less 
than 2% for measuring fat volumes on average in any muscle or compartment.   
 Ankle Dorsiflexion and Plantarflexion Peak Torque  
  Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque as measures 
of muscle performance were assessed using a Biodex Multijoint System 3 Pro isokinetic 
dynamometer (Biodex Medical Systems, Shirley, NY).  The tests were performed at 
angular velocities of 60○/s.  All participants were given 3 practice trials to ensure they 
were comfortable with the test.  The mean values for peak torque were calculated for 3 
trials.   
 Activity Monitoring 
  Participants were given an activity monitor (StepWatch by Orthocare) and were 
instructed to wear the monitor around their ankle during all waking hours to determine 
baseline activity levels.  The participants were given the monitor for at least 9 
consecutive days calculating an average of 7 days.  The first and last days of wear were 
deleted because a full 24 hours would not be recorded.  For a day to be included, the 
monitor had to be worn for at least 8 hours, and at least 1 weekend day was included in 
the 7 day average.  The device records strides per day and steps per day were calculated 
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by multiplying strides by 2 (1 stride equals 2 steps).  Results of validity tests performed 
in our laboratory indicate a mean absolute error of 1.1% (SD, 3.1%) for healthy obese 
subjects and 1.8% (SD, 2.4%) for subjects with DM+PN (13).  Results of the activity 
monitor were used to screen subjects who were inactive or already too active (i.e. 
walking less than 2,000 steps per day or greater than 10,000 steps per day) and to 
prescribe specific walking distance to start their progressive walking program as 
described below. 
Exercise Program 
 The 20 participants were randomly assigned to CON or EX condition. 
Randomization methods were successful as there were no differences between the groups 
on the primary outcome variables before the study (P>0.05). Subjects who were assigned 
to the CON group were given an opportunity to participate in the EX program after their 
12 weeks in the CON group.  Five subjects participated in both the CON and EX groups. 
The CON group received foot screenings and education regarding foot care every two 
weeks over a twelve week period for a total of 6 visits.  The EX group participated in a 
weightbearing exercise program three times a week for twelve weeks.  The exercises 
included in this program were adapted from the “Feet First” intervention (10), and those 
used in prior interventions that reduced falls in frail older adults and those with peripheral 
neuropathy (18).  Where progression for an activity was not described in the published 
study, we added an appropriate exercise progression to maximize progressive 
improvements.  Activity performance was supervised by a physical therapist.  The 
exercise sessions began with flexibility and stretching exercises. The balance exercises 
followed a progressively challenging program in which external support decreased and/or 
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the perturbation to a balanced individual increased (e.g. more compliant surface, 
movement of arms/legs).  The strengthening exercises were focused on the ankle 
dorsiflexor and plantarflexor muscles for both groups using body weight resistance (i.e. 
heel raises, bilateral progressing to unilateral for the plantar flexor muscles; stair-
climbing and coming sit-to-stand for hip, knee, and ankle extensor muscles) rather than 
machines or weights in an effort to make the exercises easier to continue after the end of 
the study.     
The aerobic intervention included walking on a treadmill for a duration 
individually calculated for the subject based on their own average step count collected 
over 7 days using a Step Watch Activity Monitor as described above. The goal was for 
subjects to increase their average step count 10% every 2 weeks by increasing their daily 
step count 24% on the 3 days that they participated in the exercise program.  For 
example, a subject with a beginning average step count of 5950 step/day had a 2 week 
goal to walk an average of 6548 step/day.  This goal would be achieved by walking at 
their self-selected pace (40-60% estimated heart rate) an additional 1428 steps (about 14 
minutes) on each of the 3 treatment days and with no change in regular activity on the 
other 4 days. This modest increase in activity (10% increase every 2 weeks) would result 
in the subject walking approximately 10,700 steps/day at the end of 12 weeks (~80% 
increase), and would meet the surgeon general’s expectation for 10,000 steps per day and 
the ADA’s guideline for 30 min/day of walking on most days.  Subjects wore a heart rate 
monitor to assist the physical therapist in assuring that the exercise intensity was within 
the mild/moderate range (40-60% of max heart rate). Exercise participation was 
modified, postponed, or stopped based on guidelines established by the ADA and ACSM 
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(1).  Exercise was postponed if 1) blood glucose >300 mg/dl, 2) resting systolic BP of 
>200 mm Hg, 3) resting diastolic BP of >110 mm hg. If blood glucose was <80-100mg/dl 
carbohydrates were ingested.   
Precautions to avoid skin injury 
 Before and after each exercise session, the physical therapist and the participant 
each performed a visual inspection of the participant’s feet and footwear.  A digital 
photograph was taken before and after the exercise session to document the skin 
condition.  Foot skin temperature was recorded using a handheld infrared thermometer 
(Xilas) before and after each session as described previously (19).  The temperature was 
recorded at 7 sites on the plantar surface of the foot where risk for skin breakdown is 
greatest: the great toe, the 1st, 3rd, and 5th metatarsal heads, medial and lateral midfoot, 
and the heel.  The temperature measures were used to determine areas that might be at 
risk for injury and were part of a composite assessment for skin injury that included 
redness, swelling and pain.  If there was an area of redness, swelling, pain and increased 
temperature, activity was limited and the participant was instructed to closely monitor the 
area and decrease daily activity. 
Data Analysis 
  Statistical analyses were performed using Systat for windows, version 13.0.  A 
repeated measures ANOVA was performed to determine any group by time interactions. 
Significance was set at P<0.05. 
 
 Results 
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  Following the 12 week exercise intervention, the EX group had a significant 
improvement in the six minute walk distance compared to the CON group. The EX group 
was able to increase six minute walk distance from 1266 feet to 1352 feet while the CON 
group changed from 1409 feet to 1398 feet (P=0.04). Table 2.  There was no difference in 
PPT scores after a 12 week exercise program (EX 27 to 29 vs. CON 29 to 30) . There was 
no difference in measures of dorsiflexor peak torque (EX 6.8 to 7.7 vs. CON 5.3 to 3.6 
Nm) or plantarflexor peak torque  (EX 51.9 to 56.9 vs. CON 54.2 to 57.8 Nm) after a 12 
week exercise program.  There was no significant difference in IMAT volumes (EX 100 
to 103 vs. CON 84 to 93 cm3) or calf muscle volumes (EX 431 to 425 vs. CON 424 to 
420 cm3) after a 12 week exercise program (P>0.05).   
    
Conclusions 
 In this study, we found that a group of people with DM+PN were able to tolerate 
a 12 week progressive exercise program and were able to increase their 6 minute walk 
distance, but showed few other measured changes in calf muscle structure, strength or 
physical performance.  Lord et al (20) and Harada et al (21) demonstrated that 6 minute 
walk distance appears to provide a measure of overall mobility and physical functioning 
in an older population rather than a specific measure of cardiovascular fitness which 
indicates that the EX group improved mobility and physical functioning overall in 
comparison to the CON group. However, the average 6 minute walk distance for healthy 
55-75 year olds has been reported to be 2161 feet (22), so even with this improvement in 
six minute walk distance, the EX group with DM+PN is still limited in comparison to 
healthy controls. While the EX group continues to have limitations in comparison to 
healthy controls, the change in six minute walk distance is consistent with a meaningful 
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change (>20m or >66 feet) as reported by Perera et al. (23).  The change in six minute 
walk distance that we report is consistent with another recent study involving supervised 
walking in people with diabetes, but without peripheral neuropathy (24).  This study by 
Negri et al. reports changes in six minute walk distance that are larger than what we 
report here, but it is important to note that people with diabetes and neuropathy are able 
to increase six minute walk distance like their peers without neuropathy. 
 The EX group was able to tolerate the 12 week exercise program and increase 
their six minute walk distance with a minimum of complications.  The EX group attended 
an average of 85% of the exercise sessions with a total of 4 foot-related complications.  
One person had an injury from trimming his own toenails, one person had a small 
abrasion on the second metatarsal head from walking barefoot at home that resolved 
within 3 days, and one person had a full-thickness wound on the 5th metatarsal head that 
appeared after callus was removed during a visit to the podiatrist. One person suffered a 
calf strain during exercise, but was able to continue to exercise with a lower intensity 
(shorter time on treadmill, fewer heel raises) and the strain resolved within one week.  
The CON group had two foot-related complications.  One person had a cut on the great 
toe due to walking barefoot at home, and one person had an open lesion between the 4th 
and 5th toe.  Both lesions resolved within 2 weeks. The annual population based incidence 
of diabetic full-thickness foot ulcers ranges from 1.0-4.1% (25).   Due to a relatively low 
incidence rate of ulceration, we are unable to truly detect differences in ulceration rates in 
this small sample.  We believe the daily pre-post exercise visual inspection to the feet 
helped to minimize skin injury.  In addition, it has been reported (26) that high variability 
in activity may contribute to plantar ulceration in people with DM+PN.  It is possible that 
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consistently attending the exercise sessions and monitoring overall activity helped to 
maintain a consistent activity level and reduced the risk of ulceration in this study 
population. 
 While six minute walk distance improved in the EX group as expected, we had 
several unexpected findings from this study.  The 12 week progressive exercise program 
did not have a measureable impact on calf muscle volume, IMAT volume, dorsiflexor or 
plantarflexor peak torque.  Physical performance as measured by PPT score was also 
unchanged after exercise, which is different from what we had expected.  Other 
investigators have reported significant reduction in IMAT, increased muscle mass in the 
thigh and increased muscle strength after an exercise program for people with diabetes 
who do not have peripheral neuropathy (8).  This study involved the use of eccentric 
exercise and higher resistance than in our study.  In our study, we did not find changes in 
IMAT, muscle, or muscle strength in the calf after an exercise program.  It is possible 
that the intensity of our strengthening exercises was not sufficient to cause changes like 
those that Marcus et al. report.  Our study population was specifically people with 
diabetes and peripheral neuropathy rather than those with diabetes alone, so it is possible 
that the presence of neuropathy minimized the ability of the calf muscles to respond to 
the exercise program in the manner that we anticipated. 
 Goodpaster et al (7) has reported that older adults who participate in an exercise 
program that uses walking as a main intervention were able to maintain muscle strength 
and minimize IMAT infiltration in comparison to a group who did not exercise.  In that 
study, the comparison group lost strength and gained IMAT, whereas our CON group 
remained unchanged in these measures.  In that particular study, the exercise intervention 
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was for one year rather than 12 weeks, so it is possible that with a longer intervention or 
longer follow up, we might have noticed similar results (i.e. greater decline in CON 
group and maintenance of muscle strength in EX group).  As in the Marcus study, 
Goodpaster et al measured IMAT and muscle in the thigh rather than the calf.  Other 
investigators (5) have noted that people with diabetes and peripheral neuropathy have 
more severe involvement distally compared to proximally. It is possible that our 
intervention could have had an effect on the thigh, but we did not measure thigh changes 
in this particular study. 
 In the “Feet First” randomized controlled trial (11), a population with DM + PN 
participated in an exercise program and was followed for one year.  These investigators 
also did not see a change in muscle strength, but the intensity of the walking program and 
the strengthening exercises were less than in our study.  In addition, part of their study 
was done by the participants at home and the authors report that compliance with the 
exercise was a problem, which could have limited the potential to observe meaningful 
changes in this population.  We had a compliance rate of 85% in this study, so we believe 
that the lack of changes that we report is not due to poor compliance. 
 This study provides important information about exercise in people with DM + 
PN, but there are limitations that should be considered.  First, this study has a small 
sample size and was not powered to detect subtle changes in outcome measures.   
Furthermore, we included only people already walking 2000-9000 steps per day and it is 
unknown whether these results apply to people with more severe involvement or DM 
complications. Also, there were 5 people who were in the CON group who then 
completed the exercise intervention, so these groups are not truly independent of each 
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other.  In addition, we did not measure the thigh muscle or thigh muscle performance, so 
it is possible that the exercise program had an effect on the lower extremities that we are 
not capturing.  Our measures of IMAT and muscle volume are gross morphological 
measures, and we do not have a measure of changes that might be occurring on a smaller 
scale such as mitochondrial function in the muscle.  Finally, we do not have a follow up 
on these subjects beyond the end of the exercise program, so we are unable to comment 
on the longer term effects of the exercise program compared to those who do not 
exercise. 
 Despite these limitations, this study provides evidence that people with DM + PN 
are able to participate in a progressive walking and strengthening program and 
demonstrate improved overall mobility and function based on six minute walk distance.  
These findings are consistent with the recently updated ADA guidelines indicating that 
individuals with DM+PN and without acute ulceration may participate in moderate 
weight-bearing exercise (1). Future studies that include a larger number of subjects 
receiving a higher intensity of resistance exercise than used in this study, and evaluating 
all lower extremity muscles, are needed to determine the appropriate safe dosage and 
intensity of activity to optimize changes in muscle morphology, strength, and physical 
mobility measures in this population. 
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Table 1. Subject Characteristics. Values are means(SD). 
Group N Gender (M/F) 
Age 
(yrs) 
Weight 
(lbs) 
BMI 
(kg/m2) 
HbA1c 
(%) 
DM 
Duration 
(years) 
Vibration 
Perception 
Threshold 
(V) 
EX 10 8/2 68(9) 246(41) 35.5(6) 6.8(0.9) 11.6(7.7) 40(11) 
CON 10 6/4 66(14) 242(57) 36.5(8) 7.7(2.2) 10.3(5.5) 37(11) 
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Table 2.  Group Data Pre and Post Exercise. Values are Mean (SD) 
 Pre Post 
6MW (feet)*   
        EX Group 1266 (263) 1352 (286) 
        CON Group 1409 (293) 1398 (234) 
PPT   
        EX Group 27 (5) 29 (5) 
        CON Group 29 (3) 30 (3) 
Muscle Volume (cm3)   
        EX Group 431 (89) 425 (108) 
        CON Group 424 (128) 420 (116) 
IMAT (cm3)   
        EX Group 100 (51) 103 (50) 
        CON Group 84 (50) 93 (50) 
DF PT (Nm)   
        EX Group 6.8 (13.3) 7.7 (9.1) 
        CON Group 5.3 (6.8) 3.6 (3.2) 
PF PT (Nm)   
        EX Group 51.9 (20.2) 56.9 (28.7) 
        CON Group 54.2 (16.7) 57.8 (26.4) 
*Indicates significant Group x Time interaction based on repeated measures ANOVA and 
significant post hoc difference between pre and post measures (P<0.05) 
The groups were not different from each other on any pre test measures (P>0.05) 
 
6MW=6 minute walk distance 
PPT=modified physical performance test score 
Muscle volume=calf muscle volume measured via MRI 
IMAT=intermuscular adipose tissue volume measured via MRI 
DF PT=dorsiflexor peak torque  
PF PT= plantarflexor peak torque 
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Chapter 5 
A weight-bearing exercise program for people with diabetes and peripheral 
neuropathy: A case report 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in review: 
Tuttle LJ, Hastings MK, Mueller MJ. A weight-bearing exercise program for people with 
diabetes and peripheral neuropathy: A case report. Phys Ther. 
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ABSTRACT  
Background and Purpose  
The exercise guidelines for people with diabetes mellitus and peripheral neuropathy 
(DM+PN) have recently changed to allow moderate intensity weight-bearing exercise, 
but there are few reports in the literature describing appropriate weight-bearing exercise 
for those with DM+PN.   This case report describes a successful and safe progressive 
exercise program for an individual with DM+PN. 
Case Description 
The subject was a 76 year old man with a 30 year history of DM + PN. He participated in 
a 12 week progressive exercise program (3 times per week) involving walking on a 
treadmill, balance exercises, and strengthening exercises for the lower extremities using 
body weight resistance. 
Outcomes 
Measures were taken before and after the 12 weeks of exercise. Six minute walk distance 
increased from 1200 to 1470 feet. Physical performance test score changed from 29 to 30. 
The Foot and Ankle Ability Measure questionnaire improved from 89-98. Dorsiflexor 
and plantarflexor peak torque increased (right dorsiflexor peak torque: 4.5 to 4.6 Nm, left 
dorsiflexor peak torque:2.8 to 3.8 Nm; right plantarflexor peak torque: 44.7 to 62.4 Nm, 
left plantarflexor peak torque: 40.8 to 56.0 Nm), as did his average daily step count (6176 
to 8273 ave steps/day). Calf intermuscular adipose tissue changed from 48 to 56 cm3 and 
calf muscle volume changed from 426 to 390 cm3.   
Discussion and Conclusions 
Evidence from this case report provides clinicians with a potential exercise program for 
people with DM+PN that may be able to increase muscle strength, physical function and 
activity. 
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 People with diabetes and peripheral neuropathy (DM+PN) clearly have lower 
extremity impairments including reduced ankle muscle strength and volume.1-3  Evidence 
suggests that the lower extremity muscles in people with DM+PN have substantial 
intermuscular adipose tissue (the visible extra-cellular adipose tissue that is located 
beneath the muscle fascia and between and within muscle groups4 [IMAT]) and muscle 
atrophy compared to their peers.5   
 These muscle changes likely contribute to their limitations in physical mobility.  
Adults with DM have an odds ratio of 2.0 for having mobility limitations compared to 
those without DM.6   The incidence of impaired mobility increases with peripheral artery 
disease and/or PN; subjects with DM and lower extremity diseases had an almost 3-fold 
increase in risk of impaired mobility compared to those having neither.6 An inability to 
walk a quarter mile and to walk up 10 steps without resting are the most frequently 
reported mobility limitations.6   Little evidence exists to determine if these impairments 
in muscle and mobility can improve with exercise.  
 In addition to these documented limitations in physical mobility, individuals with 
DM+PN lack the critical level of sensory feedback to protect their feet from injury. 
Historically, their inability to monitor their own skin condition led the ADA and ACSM 
to recommend exercise that was restricted to non-weight bearing activities (2006 
guidelines).  The exercise guidelines have recently changed, however, to allow 
individuals with DM+PN and without acute ulceration to participate in moderate weight-
bearing exercise.7 This change was prompted, in part, by the recent “Feet First” 
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randomized controlled clinical trial8 that reported that people with DM+PN were able to 
participate in a low-intensity walking program and show a slight improvement in daily 
walking activity without increasing their rate of ulceration.  Despite the benefits of this 
study, this same “Feet First” study  reported no lower extremity strength changes with 
their low-intensity, community based exercise program9 and a Cochrane review of the 
literature concluded that there is inadequate evidence to evaluate the effect of 
strengthening exercise for people with DM+PN.10   Because the intervention intensity 
was quite low in the previous reports, it is unclear if people with DM+PN are able to 
increase lower extremity strength or reduce mobility impairments with an appropriately 
dosed exercise program. 
 The purpose of this case report is to describe the effects of a 12 week progressive 
walking and resistance exercise program on physical performance (6 minute walk test, 
Physical Performance Test, Foot and Ankle Ability Measure), calf muscle performance 
(dorsiflexor and plantarflexor peak torque), and calf muscle structure and composition 
(IMAT, muscle volume) in a single individual with DM+PN.  
Case Description 
Background to the case report 
  The case reported here is from an individual who participated in a randomized 
controlled trial comparing weight-bearing exercise, non weight-bearing exercise, and a 
non-exercising condition for people who have DM+PN. The overall goal of the trial is to 
determine whether people with DM+PN are able to perform weight-bearing exercise to 
increase activity level and physical mobility without increasing the incidence of foot 
ulcers or skin breakdown. The subject provided written informed consent and the study 
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was approved by the Human Research Protection Office at Washington University in St. 
Louis.   
    
 Patient 
  The subject was a 76 y.o. man, with a BMI of 27.1, with a 30 year history of Type 
2 DM. His comorbid conditions included a history of myocardial infarction, history of 
coronary artery bypass graft, and hypertension that was controlled with medication.  His 
blood sugar was controlled through oral medication.  
 Tests and Measures 
 Peripheral Neuropathy (PN) 
  The subject had severe PN based on his inability to feel any Semmes-Weinstein 
monofilament on the plantar surface of the foot and based on his vibration perception 
threshold of 50V as measured with a biothesiometer (threshold for neuropathy is 25V, 50 
V is maximum value of machine).11,12 
 Six Minute Walk Test 
  The participant performed the six minute walk test13 as a measure of physical 
function and walking endurance. The test has been validated in obese adults.14  The 
participant walked back and forth in a hallway between 2 cones that were placed 100 feet 
apart.  The participant was told that the goal was to walk as far as possible in 6 minutes.  
Six minute walk distance was recorded as total distance walked in feet. 
 Physical Performance Test (PPT) 
  The modified 9-item PPT was used to assess physical function. This test is 
designed to mimic activities of daily living and includes items such as stair climbing, and 
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coming sit-to-stand. The 9-item PPT has been shown to correlate well with disability and 
frailty.15  Each of the items is scored on a scale of 0-4 based on the time it takes to 
complete the task. Each task is performed twice and the average time is used to determine 
the 0-4 score.  A maximum score is indicated by a score of 36. 
 Foot and Ankle Ability Measure (FAAM) 
  The FAAM is a reliable, responsive, and valid self-report measure of physical 
function for individuals with a broad range of musculoskeletal disorders of the lower leg, 
foot, and ankle.16 The questions investigate the subjects perception of 26 activities of 
daily living (i.e. walking on even ground, walking up hills, stepping up and down curbs, 
home responsibilities, recreational activities).  The FAAM was found to be more 
responsive to changes in functional status compared to the SF-36 and has a high test-
retest reliability of 0.89.16  A higher score on the FAAM indicates better physical 
function. 
 Ankle Dorsiflexion and Plantarflexion Peak Torque  
  Concentric isokinetic ankle dorsiflexor and plantarflexor peak torque as measures 
of muscle performance were assessed using a Biodex Multijoint System 3 Pro isokinetic 
dynamometer.††  The tests were performed at angular velocities of 60○/s.  He was given 3 
practice trials to ensure he was comfortable with the test.  The mean values for peak 
torque were calculated for 3 trials.   
 Intermuscular Adipose Tissue (IMAT) and Muscle Volumes 
 Intermuscular adipose tissue and lean muscle volumes were quantified using MRI 
on the right leg.  The MRI scans were performed with the participant in a supine position 
                                                           
††
 Biodex Medical Systems, 20 Ramsay Road, Shirley, NY 11967. 
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with a Siemens CP extremity coil placed over the right calf muscle.  The MRI 
measurements were performed with a 3.0-Tessla magnet‡‡ with a pulse sequence of 
TE=12 milliseconds, TR=1,500 milliseconds, matrix=256x256; both a fat saturated and a 
non fat saturated image were collected.5  Thirty transverse slices were collected 
beginning at the joint space of the knee and proceeding distally.  The slices were 7mm 
thick with no interslice gap.  Nine consecutive slices were selected to calculate muscle 
and IMAT volumes.  Volumes were quantified using a PC workstation and custom 
Matlab software.  The software uses voxel brightness to distinguish between muscle and 
adipose tissues. The subcutaneous adipose tissue was removed from each image by 
drawing a line along the deep fascial plane surrounding the calf muscle so that only the 
fat within and between the muscles (IMAT) was remaining. The software uses edge 
detection algorithms to assist the user in separating the subcutaneous fat from the muscle 
as well as separating individual muscles and muscle compartments.  IMAT and muscle 
volumes are reported in cm3.  Based on test-retest reliability of 21 subjects, the error in 
measuring muscle volume is less than 1% and less than 2% for measuring fat volumes on 
average in any muscle or compartment.   
 Activity Monitoring 
  The participant was given a StepWatch activity monitor§§ and was instructed to 
wear the monitor around his ankle during all waking hours to determine baseline activity 
levels.  The participant was given the monitor for at least 9 consecutive days calculating 
an average of 7 days.  The first and last days of wear were deleted because a full 24 hours 
                                                           
‡‡
 Siemens Corp, Citicorp Center, 153 E. 53rd St., New York, NY 10022 
§§
 Orthocare Innovations, 840 Research Parkway, Suite 200,Oklahoma City, OK 73104 
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would not be recorded.  For a day to be included, the monitor had to be worn for at least 8 
hours, and at least 1 weekend day was included in the 7 day average.  The device records 
strides per day and steps per day were calculated by multiplying strides by 2 (1 stride 
equals 2 steps).  Results of validity tests performed in our laboratory indicate a mean 
absolute error of 1.1% (SD, 3.1%) for healthy obese subjects and 1.8% (SD, 2.4%) for 
subjects with DM+PN.11  Results of the activity monitor were used to prescribe his 
specific walking distance to start his progressive walking program as described below. 
  The subject was determined to be appropriate for participation in this exercise 
program due to the presence of DM+PN and lack of any severe foot deformities or co-
morbidities that might limit his ability to tolerate 60 minutes of exercise.   
Exercise Program 
 The subject participated in a weightbearing exercise program three times a week 
for twelve weeks.  The exercises included in this program were adapted from the “Feet 
First” intervention,8  and those used in prior interventions that reduced falls in frail older 
adults and those with PN.17  Where progression for an activity was not described in the 
published study, we added an appropriate exercise progression to maximize progressive 
improvements.  Activity performance was supervised by a physical therapist.  The 
exercise sessions began with flexibility and stretching exercises. The stretches included: 
toe stretches aimed at stretching the toe extensor muscles, a supine hamstring stretch, 
prone knee flexion, rocking on hands and knees, and a standing calf stretch. Each stretch 
was performed twice with a 30 second hold. The balance exercises followed a 
progressively challenging program in which external support decreased and/or the 
perturbation to a balanced individual increased (e.g. more compliant surface, movement 
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of arms/legs).  The strengthening exercises were focused on the ankle dorsiflexor and 
plantarflexor muscles using body weight resistance (i.e. heel raises, bilateral progressing 
to unilateral for the plantar flexor muscles; stair-climbing and coming sit-to-stand for hip, 
knee, and ankle extensor muscles) rather than machines or weights in an effort to make 
the exercises easier to continue after the end of the study (Table 1).    
  The aerobic intervention included walking on a treadmill for a duration 
individually calculated for the subject based on his own average step count collected over 
7 days using a Step Watch Activity Monitor as described above. The goal was for the 
subject to increase his average step count 10% every 2 weeks by increasing his daily step 
count 24% on the 3 days that he participated in the exercise program. In this case, he 
began with a step count of 6176 steps/day and the goal was for him to reach 10,712 
steps/day (See Figure 1 for step count weekly goals).  The subject wore a heart rate 
monitor to assist the physical therapist in ensuring that the exercise intensity was within 
the mild/moderate range (40-60% of max heart rate). Exercise participation was 
modified, postponed, or stopped based on guidelines established by the ADA and 
ACSM.7  Exercise was postponed if 1) blood glucose >300 mg/dl, 2) resting systolic BP 
of >200 mm Hg, 3) resting diastolic BP of >110 mm hg. If blood glucose was <80-
100mg/dl carbohydrates were ingested.   
Precautions to avoid skin injury 
 Before and after each exercise session, the physical therapist and the participant 
each performed a visual inspection of the participant’s feet and footwear.  A digital 
photograph was taken before and after the exercise session to document the skin 
condition.  Foot skin temperature was recorded using a handheld infrared thermometer 
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(Diabetica Temptouch***) before and after each session as described previously.18  The 
temperature was recorded at 7 sites on the plantar surface of the foot where risk for skin 
breakdown is greatest: the great toe, the 1st, 3rd, and 5th metatarsal heads, medial and 
lateral midfoot, and the heel.  The temperature measures were used to determine areas 
that might be at risk for injury and were part of a composite assessment for skin injury 
that included redness, swelling and pain.  If there was an area of redness, swelling, pain 
and increased temperature, activity was limited and the participant was instructed to 
closely monitor the area and decrease daily activity. 
 Adherence to Exercise 
  All exercise sessions were monitored by a physical therapist.  In order to assist 
with transportation costs, the subject received ten dollars for each exercise visit attended.  
The subject attended 86% of the scheduled exercise classes.  The subject missed 5 
exercise sessions due to illness and conflict with previously scheduled doctor’s 
appointments. 
 Outcomes 
  Data for outcome measures were obtained before and after the 12 week exercise 
program (Table 2). He was able to progress on all of the prescribed exercises and was 
able to increase his time on the treadmill at his self-selected pace of 2.0 mph from 14min 
to 24min. The subject improved his six minute walk distance from 1200 to 1470 feet.  His 
PPT score improved from 29 to 30 and his FAAM score improved from 89-98%.  The 
participants average daily step count increased from 6176 to 8273 steps/day.  Glucose 
control improved as indicated by a decrease in HbA1c from 6.9 to 6.4%.   
                                                           
***
 Diabetic solutions Inc. 12665 Silicon Drive, San Antonio, TX 78201 
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Dorsiflexor and plantarflexor peak torque increased (right dorsiflexor peak 
torque: 4.5 to 4.6 Nm, left dorsiflexor peak torque:2.8 to 3.8 Nm; right plantarflexor peak 
torque: 44.7 to 62.4 Nm, left plantarflexor peak torque: 40.8 to 56.0 Nm) (Figure 1).  
IMAT volume increased (48 to 56 cm3) and calf muscle volume decreased (426 to 390 
cm3).  He also lost 13 pounds over the 12 week intervention.  
This subject was able to tolerate a 12 week exercise program without 
complications or skin breakdown.  His only injury came from trimming his own toe nails 
and this injury resolved in less than one week.  
 Discussion 
  The guidelines from the ADA and ACSM have recently changed to indicate that 
people with DM+PN may participate in moderate weight bearing exercise.  Prior to this 
change in guidelines, it was recommended that people with DM+PN limit weight bearing 
activity due to concerns for increased risk for skin injury.  This case report provides an 
example of a moderate intensity, weight-bearing exercise program that was successful in 
safely increasing six minute walk distance, average daily step count, and ankle strength in 
a person with DM+PN.   
  The subject presented in this case report was able to increase his six minute walk 
distance from 1200 to 1470 feet after the 12 week exercise program.  The six minute 
walk test has been shown to be a measure of overall mobility and physical function19,20 
and a change of 270 feet is consistent with a substantial change as reported by Perera et 
al.21 It seems reasonable that the six minute walk distance improved as the subject was 
part of a duration based walking program.  Even though he did not increase his velocity 
during treadmill training, he was able to increase his velocity during the six minute walk 
93 
 
test. Essentially, he was training to walk and he was successful in improving his ability to 
walk. 
  In the case of this subject, PPT scores did not improve substantially (29-30).  
Based on an initial score of 29 out of 36 possible points, this particular subject did not 
demonstrate frailty or severe limitations in function, so it is possible that he had little 
room to improve on the PPT measure.  However, his FAAM score did improve by 9 
points, which is beyond the minimal detectable change (5.7 points) and minimal 
clinically important change (8 points) of the test.16  The subject reported improvements 
on the FAAM in: walking uphill, climbing stairs, going up and down curbs, squatting, 
doing heavy work (pushing/pulling, climbing, carrying), and in recreational activities. 
The FAAM is a measure of physical function that is specific to the foot, ankle and lower 
extremity activities whereas the PPT incorporates upper extremity activities as well.  The 
exercise program reported here is focused entirely on the lower extremity, so it is 
possible that the FAAM is a more sensitive measure of improvement than the PPT in this 
case. 
  Dorsiflexor and plantarflexor strength measures (peak torque) responded 
differently from each other in this intervention.  The dorsiflexor peak torque values did 
not change as much as the plantarflexor peak torque, but the plantarflexor peak torque 
increased by 37-40%.  There are several reasons that could account for this difference in 
response.  First, more of the exercises in this program were focused on increasing 
strength in the plantarflexors.  The primary exercise for the dorsiflexors was heel stands, 
while the plantarflexors had toe raises (heels up), stair climbing, and sit to stand.  It has 
been reported previously that dorsiflexion is impaired in people with DM+PN.3  It is 
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possible that due to the process of DM and DM+PN, the dorsiflexors may be harder to 
strengthen or less able to adapt than the plantaflexors. 
  The “Feet First” study9 described a low-intensity intervention for people with 
DM+PN aimed at increasing walking activity and improving strength, but they report no 
strength changes in their exercise program. The intervention that we describe here is 
more intensive than the “Feet First” study based on our goal of increasing step count by 
10% every 2 weeks.  This subject was able to tolerate this more aggressive program 
without injury or complications and was able to increase his average daily step count 
from 6176 to 8273 steps per day (34% increase) (Figure 1). However, this subject did not 
actually meet the target goal of increasing step count by 10% every 2 weeks (goal of 
10,712 steps/day).  Because he was walking at his self selected pace and we based the 
walking program on a predetermined length of walking time, his actual number of steps 
taken during the treadmill walk was less than what was required for the 10% increase to 
occur.   
  While this subject was able to increase his average daily activity, ankle muscle 
strength and six minute walk distance, he lost weight overall and actually lost muscle 
volume in the calf and gained IMAT in the calf.  Previous studies of a walking program 
in older adults22 indicate that an exercise program can attenuate strength loss and IMAT 
gain in the thigh.  It is unknown whether people with DM+PN are able to respond in a 
similar manner and it is unknown whether neuropathic muscle is able to adapt or what the 
intensity of the stimulus should be to elicit change in muscle structure.  Based on this 
case study, it appears that change in calf muscle volume and calf IMAT volume are not 
directly related to change in muscle performance or physical function, but this is in 
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conflict with other reports in the literature.5  Future studies should focus on teasing out 
the relationship between IMAT and muscle function and its response to exercise.   
  Other investigators8 have indicated that muscle quality (peak torque/muscle 
volume) may be a key component in muscle function.  In this case study, strength 
increased despite a decrease in muscle volume which would indicate an improvement in 
muscle quality as defined by peak torque/muscle volume.  It is possible that the 
underlying contractile properties of the muscle were changed which could account for the 
increase in peak torque independent of a change in muscle volume.  It is also possible 
that the improvement in muscle strength is due to a change in the nervous system rather 
than a change in the muscle structure.  We do not have measures that answer these 
questions, but they should be investigated in future studies. 
  Of note, this subject’s HbA1c dropped by 0.5% from 6.9% to 6.4% indicating an 
improvement in glucose control over the 12 weeks of exercise.  Other exercise studies 
have reported HbA1c reductions of 0.6-1.6% with combined aerobic and resistance 
exercise programs of 8weeks-24months.23-27 In all of these studies, the exercise programs 
were of higher intensity than the one we report here, and further study is needed to 
determine if a higher intensity exercise program is safe and can result in larger drops in 
HbA1c in people with DM+PN.  We can only speculate that perhaps even with this 
moderate intensity exercise program, the muscles improved insulin sensitivity which 
could be responsible for the improvement in HbA1c.  More research is needed to 
determine if this speculation is accurate. 
  While this case study provides important information for clinicians, there are 
limitations to be considered.  First, this is a case study of a single subject and it is unclear 
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whether these results are generalizable to the larger population of people with DM+PN.  
This person did not have severe foot deformity or a history of plantar ulcer and more 
studies are needed to determine the safety of this type of exercise for people with these 
diabetic complications.  We believe that our precautions of a detailed foot exam before 
and after exercise are important components in people with DM+PN exercising safely.  
We also used temperature measures from the plantar surface of the foot as a means of 
identifying areas that might be at risk for skin breakdown.18  However, there were 
multiple false positives (cases where the temperature difference was >4 degrees between 
the right and left foot without other signs or symptoms indicating tissue damage). For this 
subject, we concluded that the detailed visual foot examination before and after exercise 
was adequate to prevent injury. Additional research is needed to investigate the 
usefulness of temperature readings in populations at risk for skin injury. 
  This case report provides an example of a weightbearing exercise program that 
was successfully implemented for a person with DM+PN.  He was able to complete the 
program without injury and increase six minute walk distance, increase plantarflexor 
peak torque, and increase his average daily step count.  More work is needed to 
determine the appropriate intensity of exercise to elicit changes in muscle structure and to 
determine the safety of high intensity resistance and/or aerobic exercise in people with 
DM+PN. 
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Table 1. Exercises performed during week 1 and week 12.  Progression was determined 
at each exercise session based on the subject’s subjective report of an exercise becoming 
easy and his tolerance for increasing his repetitions on an exercise. 
Week 1 Week 12 
Toe crunches, 10 reps 2 times Toe crunches, 35 reps 2 times 
Single leg stand with one hand support, 30 
seconds 2 times 
Single leg stand with no hand support, 30 
seconds 2 times 
Step sideways and step backwards, 10 steps 
each 2 times Step over 5 cones, 3 times 
2 leg heel stands (toes up), 10 reps 2 times 2 leg heel stands (toes up) 20 reps 2 times 
2 leg toe raises (heels up), 10 reps 2 times Single leg toe raises (heels up) 40 reps 2 times 
Sit to stand, 5 reps 2 times Sit to stand 20 reps 2 times 
Step Ups with one hand support, 10 reps 2 
times Climb 2 flights of stairs, 2 times 
14 min walk on treadmill, self-selected pace 24 min walk on treadmill, self-selected pace 
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Table 2.  Outcome measures. 
Measure Pre Exercise Post Exercise 
Six Minute Walk Distance (feet) 1200 1470 
PPT Score 29 30 
FAAM Score (%) 89 98 
Self-Report FAAM Score (%) 98 100 
Dorsiflexor Peak Torque (Nm) Right/Left 4.5/2.8 4.6/3.8 
Plantarflexor Peak Torque (Nm) Right/Left 44.7/40.8 62.4/56.0 
Average Daily Step Count 6176 8273 
HbA1c (%) 6.9 6.4 
IMAT volume (cm3) 48 56 
Muscle volume (cm3) 426 390 
Weight (lbs) 178 165 
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Figure 1: Step Activity Monitor Data by Week. 
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Summary of Major Findings 
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Summary of Key Findings 
 The objectives of this research were to describe skeletal muscle structure in people 
with diabetes and peripheral neuropathy, to determine whether neuropathic muscle 
structure and composition is associated with movement impairments and functional 
limitations, and to determine whether neuropathic muscle can be modulated by activity 
level and/or an exercise intervention. 
 Chapter 2 asked the questions: does the presence of diabetes mellitus (DM) and 
peripheral neuropathy (PN) have an additive affect on IMAT in the calf beyond the 
presence of obesity? And how does IMAT impact function in a group with DM, a group 
with DM+PN and a group with NoDMPN?  Our results suggest that the presence of DM 
and DM+PN do not have an additive affect on calf IMAT as there were no differences in 
calf IMAT between the 3 groups.  IMAT was associated with worse physical 
performance, however, and both the DM and DM+PN group had lower measures of 
physical performance in comparison to the NoDMPN group.  In addition, it appears that 
calf muscles may be affected by IMAT differently. Specifically, the gastrocnemius 
muscle had the highest ratio of IMAT/Muscle Volume of any other calf muscle.   
 These results add to our knowledge of IMAT in that it continues to be related to 
physical performance, but DM and PN do not seem to increase IMAT accumulation 
independently of obesity.  However, the group with DM and DM+PN had lower 
measures of physical performance, indicating that the presence of pathology such as DM 
and DM+PN impact physical performance beyond what is fully explained by IMAT in 
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the calf.  This is also the first study to report muscle specific differences in IMAT 
accumulation, which will warrant future study. 
 Chapter 3 asked the question: how active are people with DM+PN and is activity 
(average daily step count) related to calf IMAT in people with DM+PN? Our results 
show that people with DM+PN are able to maintain a higher level of activity on average 
than what we originally expected.  Activity was inversely associated with IMAT, but was 
not associated with measures of performance or glucose control. Interestingly, IMAT was 
associated with measures of muscle performance and physical function, indicating that 
activity level may be a modifiable factor with the potential to impact IMAT and possibly 
impact physical function in people with DM+PN. 
 Chapters 4 and 5 asked the question: can neuropathic muscles adapt after an 
exercise program and can people with DM+PN improve physical function after an 
exercise program?  Our results show that in response to a duration based walking 
program, overall, people with DM+PN are able to increase 6 minute walk distance.  
Changes in muscle strength as a group were variable, but some individuals were able to 
increase average activity, increase muscle strength and improve physical performance.  
Interestingly, these changes occurred without a consistent change in muscle volume or 
IMAT. 
 In summary, our data suggests that IMAT is associated with physical 
performance, but the presence of DM+PN are key factors that influence performance 
overall.  In addition, activity level is also related to IMAT, but more study is needed to 
determine the exact exercise prescription that is safe and appropriate to cause changes in 
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muscle volume and IMAT in people with DM+PN. It is possible to have improvements in 
overall performance that are not reflected in changes in gross muscle morphology in the 
calf muscles. 
Limitations 
 There are several limitations to these studies; 1) small sample sizes, 2) potential 
for a selection bias due to recruitment for an exercise study, 3) generalizability to those 
with ulceration and foot deformity, 4) lack of activity measures for all participants, and  
5) lack of histology measures.  First, the sample sizes for these studies are relatively 
small.  It is possible that with larger sample sizes, we would have been able to better 
characterize variables that contribute to IMAT.  Secondly, the people with DM+PN who 
participated in these studies were all interested in an ongoing study involving exercise for 
people with DM+PN.  It is possible that this led us to recruit the most active and highest 
functioning people with DM+PN and we are not fully capturing a broad spectrum of the 
whole population with DM+PN.  Third, one of the requirements for participation in these 
studies was a lack of foot deformity and we had very few participants with a history of 
ulcer. These results should not be generalized to people who have these complications.  
Fourth, we do not have activity measures for the groups with DM only or NoDMPN, so it 
is possible that these groups are different from the DM+PN group in activity, which 
could be a confounding variable in our results.  Fifth, we do not have histology measures 
or measures of changes that may be occurring on a smaller level in the muscle. We do not 
know whether we would see group differences in histology between people with DM, 
DM+PN and NoDMPN, or whether the exercise program was perhaps altering muscle 
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composition in a manner that we are not able to observe due to the gross MRI measures 
that we are using. 
Clinical Implications 
 Based on these results, people with DM+PN display lower levels of physical 
function than their peers, although it is unclear whether IMAT is the key predictor of this 
decline in physical function and whether or not interventions aimed at decreasing IMAT 
will result in improved physical function.  People with DM+PN are able to tolerate high 
levels of physical activity without suffering from skin breakdown.  Health care workers 
should continue to educate people with DM+PN on the importance of increased physical 
activity and the necessary precaution of a detailed foot examination daily to prevent skin 
injury.  While the 12 week duration-based intervention did not successfully change 
muscle or adipose tissue morphology in the calf, the participants were successful in 
increasing six minute walk distance.  This speaks to the importance of specificity of 
training—these participants were training using walking as the primary exercise and they 
were indeed able to walk further.   
Future Studies 
 Future studies are needed with larger sample sizes and with imaging data 
collected on the entire lower extremity rather than just the calf or just the thigh to 
determine whether IMAT accumulation is muscle specific throughout the lower 
extremity. Our data suggest that the gastrocnemius is affected by IMAT accumulation 
more so than other muscles and it is unknown whether other muscles in the lower 
extremity are preferentially affected, but there is evidence in the literature that there are 
higher amounts of IMAT in the foot muscles compared to more proximal muscle in the 
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lower extremity in people with DM+PN.  Future studies should attempt targeted 
interventions for the gastrocnemius muscle in an effort to determine if IMAT can be 
changed. Also, studies with more longitudinal data and longer follow ups that what is 
presented here are needed.  The natural history of the disease of DM and DM+PN is one 
of decline in strength and function, so a longer follow up would provide more insight on 
the effects of higher levels of activity or of an intervention. 
 The ideal magnitude, duration and type of intervention to cause safe changes in 
the morphology of neuropathic muscle remain unclear.  The American Diabetes 
Association and the American College of Sports Medicine have only recently changed 
their guidelines to indicate that people with DM+PN may participate in moderate 
intensity exercise. Future studies should examine a higher intensity exercise program—
both aerobic and resistance based—to determine the impact this has on muscle structure 
and physical performance and the safety of high intensity exercise in people with 
DM+PN.  Based on our data, it is unclear whether neuropathic muscle has the potential to 
adapt muscle morphology in response to exercise, but a higher intensity strengthening 
program would provide clinicians with more useful information in this regard.  In 
addition, measures of nerve function such as nerve conduction velocity testing would 
provide information about adaptation in this population.  It is possible that the exercise 
program altered the nervous system in some way and that accounts for the changes in 6 
minute walk distance and would explain why we did not see changes in muscle 
morphology.  
 Overall, our results suggest that people with DM+PN have lower levels of 
physical performance than their peers and increased IMAT is associated with poor 
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physical performance and may be muscle specific.  Increased activity levels are 
associated with decreased IMAT volume, and people with DM+PN are able to safely 
increase their walking distance following an exercise intervention, but we did not see a 
change in muscle composition.  Additional research is needed to determine the specific 
roles of IMAT in skeletal muscle and function.  
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Appendix A 
Magnetic Resonance Spectroscopy 
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 Originally, I proposed to use magnetic resonance spectroscopy to investigate 
intramyocellular and extramyocellular lipid content in the calf muscles of people with 
diabetes and peripheral neuropathy.  I was able to collect and analyze these data, 
however, because of difficulty in finding appropriate voxel placement in muscles with 
high amounts of visible adipose tissue and difficulty in interpreting the results from these 
scans, the information has been included in this appendix rather than in a primary chapter 
of the dissertation. 
 Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that 
allows investigators to examine metabolites within the muscle.  1H-MRS makes it 
possible to observe intramyocellular lipids (IMCL) and extramyocellular lipids (EMCL) 
within the muscle.  Intramyocellular lipids are stored in the form of lipid droplets in the 
cytoplasm in close contact with the mitochondria in the muscle cell (1). The ability to 
observe IMCL via 1H-MRS gained popularity when it became clear that IMCL can be 
recruited for use during strenuous exercise (2).  The observation of increased IMCL in 
diabetic and insulin-resistant individuals supported the hypothesis that increased IMCL 
within the muscle could be a part of skeletal muscle insulin resistance (3-6). 
 Recently, measures of IMCL have been used to measure outcomes in a cohort of 
elderly obese individuals participating in either a diet only intervention or a combined 
diet and exercise intervention (7).  The preliminary results of this study show an increase 
in IMCL in the soleus muscle in the diet and exercise group and no change in the IMCL 
content of the medial gastrocnemius.  It is possible that increased IMCL in the soleus 
muscle may have been a positive adaptation in the diet and exercise group as the result of 
endurance activity such as the IMCL noted in highly trained athletes (8).  Any 
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information on how neuropathic muscle responds or fails to respond to an intervention 
will provide health care providers with important information about how diabetic and 
neuropathic muscle adapts. 
 The goal was to determine if there was a difference in IMCL and EMCL in the 
gastrocnemius and soleus muscles in a group with diabetes (DM), a group with diabetes 
and peripheral neuropathy (DM+PN) and an age and BMI matched group without 
diabetes and peripheral neuropathy (NoDMPN).  A secondary goal was to determine if 
IMCL and EMCL in the gastrocnemius and soleus muscle changes in response to an 
exercise program for people with DM+PN. 
 Methods 
  IMCL and EMCL values were quantified using proton spectroscopy on the right 
calf of each participant with a 3.0-T superconducting MRI instrument using a point 
resolved spectroscopy (PRESS) single-voxel technique (9). The participants were 
positioned in supine with an extremity coil over the calf. Spectra were collected at echo 
times of 30 and 60 ms to approximate and correct for the T2 decay of the signals (9). An 
initial scout scan was performed in order to localize the calf musculature.  A 1cm3 voxel 
region of interest was chosen, avoiding vessels and apparent adipose depots in the medial 
gastrocnemius muscle (2 voxels) and the soleus muscle (3 voxels). Fig 1. The data was 
processed and analyzed using jMRUI 3.0 with an AMARES fitting algorithm and using 
prior knowledge of the water and IMCL frequencies (10-13). Fig 2. An average of the 
IMCL from the voxels in each muscle was used for analysis and are reported as a 
percentage of the water peak in arbitrary units. 
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  A one-way ANOVA was used to determine group differences (DM vs. DM+PN 
vs. NoDMPN) and a repeated measures ANOVA was used to determine differences in 
groupxtime. A power analysis was conducted based on the means and standard deviations 
listed in Table 2 using GPower 3.0.10 software to determine the sample size necessary to 
detect differences using repeated measures ANOVA and the results of this analysis are 
listed in Table 2. 
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 Results 
 Table 1: Group differences in IMCL and EMCL. Values are mean (SD). P-values 
are from one way ANOVA. 
 DM DM+PN NoDMPN P-Values 
Soleus  
IMCL(AU) 
2.8(1.9) 
N=9 
3.1(2.5) 
N=18 
3.7(5.6) 
N=8 0.83 
Soleus 
EMCL(AU) 
3.1 (1.8) 
N=9 
5.6 (5.4) 
N=18 
5.6 (6.5) 
N=8 0.46 
Gastrocnemius 
IMCL(AU) 
2.1(1.7) 
N=8 
3.5(4.7) 
N=10 
1.6(1.4) 
N=8 0.42 
Gastrocnemius 
EMCL(AU) 
4.5 (3.4) 
N=8 
11.4 (19.6) 
N=10 
5.7(5.3) 
N=8 0.48 
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Table 2: Pre and post exercise IMCL and EMCL values.  Values are mean (SD). 
 Pre Post Power Analysis 
SOL IMCL   1962 
        EX Group N=9 4.9 (7.2) 4.9 (5.0)  
        CON Group N=7 3.9 (3.7) 5.9 (8.1)  
SOL EMCL   830 
        EX Group N=9 6.3 (6.7) 7.3 (5.9)  
        CON Group N=8 7.5 (7.5) 6.4 (7.2)  
GAST IMCL   150 
        EX Group N=6 6.6 (8.1) 2.8 (4.4)  
        CON Group N=3 4.2 (3.2) 3.0 (3.6)  
GAST EMCL   26 
        EX Group N=6 13.2 (17.5) 6.5 (8.1)  
        CON Group N=3 2.3 (3.2) 3.8 (3.2)  
No groupxtime differences (P>0.05) 
Power Analysis: total number of subjects needed to determine group differences using a 
repeated measures ANOVA. 
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Discussion 
 There were no differences in IMCL and EMCL values between the DM, DM+PN 
and NoDMPN groups (Table 1).  There was also no change in IMCL and EMCL in the 
EX group or the CON group from pre to post exercise testing (Table 2).  There are 
several limitations to be considered.  First, the IMCL and EMCL values in the 
gastrocnemius and soleus muscles are highly variable—notice that the standard 
deviations often exceed the mean value.  This high variance makes detecting group 
differences or changes over time difficult, particularly in a small sample.  Also, as noted 
in the methods, when choosing a voxel, the goal is to avoid vessels and frank adipose 
tissue.  Appropriate voxel placement becomes impossible in cases where the 
gastrocnemius or soleus has large amounts of intermuscular adipose tissue (Fig 3) and 
makes the results either invalid or difficult to interpret. The N is variable in the groups 
because of the invalid data.  The average ratio of IMAT/Muscle volume in the 
gastrocnemius muscle of the subjects with invalid data (N=19) across the DM, DM+PN 
and NoDMPN groups was 0.43 with a standard deviation of 0.53 and a range of 0.11 to 
1.848. More data is needed to determine a true threshold of IMAT infiltration that makes 
MRS data difficult to interpret due to the difficulty in voxel placement. It is unclear 
whether the results would be improved with the use of larger magnets or smaller voxel, 
but this should be considered for future studies.  While MRS provides data regarding 
IMCL and EMCL in individual muscles and allows investigators to measure fat within a 
muscle cell, it seems that this technique is not feasible as a measure in populations with 
large amounts of IMAT such as people who are obese, and have DM and PN due to 
difficulty in voxel placement as well as interpretation of large fat peaks using current 
analysis methods.   
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Figure 1. Example of voxel placement in the medial gastrocnemius muscle of a subject 
with low intermuscular adipose tissue. 
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Figure 2. Example of a spectrum collected using MRS protocol.  Notice the large water 
peak and the much smaller IMCL and EMCL peaks to the right of the water peak. 
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Figure 3.  Examples of subjects with large amounts of IMAT in the gastrocnemius and 
soleus muscles making voxel placement in areas without adipose tissue impossible. 
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Appendix B 
DXA vs. MRI for IMAT analysis 
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 There are multiple ways to determine body composition including amount of fat 
and muscle in a particular area of the body.  Dual-energy x-ray absorptiometry (DXA) 
can be used to distinguish soft tissue from bone and to distinguish fat from lean (muscle) 
tissue.  DXA is reliable and valid1 and allows the user to look at regional areas of fat and 
lean muscle, such as the leg. DXA has the benefit of being non-invasive, as well as a very 
fast imaging tool (6 minutes for a whole body scan), but has the drawback of using 
radiation and has limited resolution. 
 MRI can also be used to determine fat and lean tissue in a region of interest due to 
inherent tissue contrast because of different amounts of water in different tissues.  MRI is 
also a non-invasive imaging tool, but the MR scans typically will take longer and will 
image a smaller area of interest.  For example, the MR protocol that is used to scan the 
calf takes 4.5 minutes to scan 21cm of the calf compared to 6 minutes for a whole body 
DXA scan.  Unlike DXA, MRI does not use radiation and has superior resolution to look 
at body structures, however the cost for MRI is significantly higher than DXA. 
 One might be interested in trying to parse out the fat between and within an 
individual muscle compartment (Intermuscular adipose tissue or IMAT), but it is unclear 
whether or not DXA would provide this capability.  It is also unclear whether the fat 
reported in DXA measures correspond entirely with subcutaneous fat or if it is able to 
capture IMAT as well. 
 Using the data set of the 45 participants from chapter 2—11 people with type 2 
diabetes [5men/6 women; aged 56(9); BMI 35.5(6.4)], 24 people with diabetes and 
peripheral neuropathy [15 men/9 women; aged 64(13); BMI 32.6(6.3)], and 10 people 
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without diabetes and without peripheral neuropathy [4 men/6 women; aged 64(9); BMI 
32.9(4.6)], I compared DXA measures and MRI measures using Pearson correlations. 
 There was a high correlation between calf total fat in cm3 via MRI (subcutaneous 
fat and IMAT) and the leg fat in grams measured via DXA (r=0.78) (Figure 1).  There 
was a low correlation between calf IMAT in cm3 measured via MRI and the leg fat in 
grams measured via DXA (r=0.20) (Figure 2).  There was also a significant correlation 
between BMI and body fat percentage as measured using DXA (r=0.60) (Figure 3), but 
there was a fair amount of variability around the trend line. 
 Based on this analysis, it is necessary to use MRI to measure IMAT, but DXA 
provides an alternate tool for measures of whole body and regional body composition.  In 
addition, DXA may provide another way to characterize obesity or regional adiposity that 
is more specific than BMI and may be more powerful when looking at specific regions of 
interest between groups. 
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Figure 1. 
 
 
 
 
 
 
 
 
 
 
R=0.78 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
R=0.20 
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Figure 3. 
 
 
R=0.60 
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Appendix C 
Exercise Intervention Daily Checklist, Stretching and Weight-Bearing Exercises
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Exercise Study for People with Diabetes and Peripheral Neuropathy 
Program in Physical Therapy, Washington University School of Medicine 
 
Daily Stat and Check Sheet -To be completed before and after every intervention session 
Date:___________________ 
Subject ID:___________________ 
DOB:_____________________ 
Weight:___________________ 
Participant comments before exercise:_______________________________________ 
Screening:  Footwear:  Adequate [] Not adequate [] (See footwear checklist for guidelines) 
 
Digital Photograph  Pulse  Blood Pressure Glucose Level 
Before  Yes []  _____  _____/_______ _____ 
After  Yes []  _____  _____/_______ _____ 
 
Plantar Skin Temperature    Med  Lateral 
Before        Great Toe Met 1 Met 3 Met 5 Midft Midft  Heel 
 Left       _______ _____ _____  _____ _____ _____ _____ 
 Right       _______ _____ _____  _____ _____ _____ _____ 
 Difference _______ _____ _____ _____ _____ _____ _____ 
***(4 degree F (2.2 degree C) difference side to side indicates participant should monitor 
skin carefully and reduce activity as per study coordinator)*** 
After 
 Left         _______ _____ _____  _____ _____ _____ _____ 
Right       _______ _____ _____  _____ _____ _____ _____ 
Difference _______ _____ _____ _____ _____ _____ _____ 
***(4 degree F (2.2 degree C) difference side to side indicates participant should monitor 
skin carefully and  reduce activity as per study coordinator)*** 
 
Barefoot Visual Inspection Describe any blisters, redness, cracking, rash, lesion, nail color, 
and describe any area with a temperature change of 4 degrees F or greater--Complete wound 
documentation form if any new lesion exists. 
 Before __________________________________________________________ 
 After ____________________________________________________________ 
 
Intervention Target heart rate range (220-age): _______________ 
  HR monitored during exercise [ ] ________ 
 20 minutes of flexibility, balance, and strengthening exercises 
 Provide group and level specific instructions WB or NWB  Level_____. 
 Blood Glucose Monitored:   Pre exercise:________   Post exercise______. 
 Minutes of walking / stationary bike: Target _______ Actual_______ 
 Step count during intervention:  Pedometer _______   SAM______ 
         RPM (bike)______ 
Exercise Precautions for all participants:  Exercise postponed because 
_____1) Blood glucose >300 mg/dl,  
_____2) Resting systolic BP of >200 mm Hg,  
132 
 
_____3) Resting diastolic BP of >110 mm hg.  
_____4) Blood glucose is <80-100mg/dl (ACSM guidelines) carbohydrates were ingested.   
_____5) Target heart rate is intended to be 40-60% of age-predicted maximum, and 
activity will be adjusted to stay within those limits using a heart rate monitor. 
 
Participant comments, complaints, or observations from Physical Therapist or study coordinator. 
  
Toe Stretch  
*Sitting, cross right foot up onto thigh 
*Grasp toes of right foot with your hand and curl the toes down 
*Then point ankle and foot down (in the direction you push on the gas pedal) 
*Hold 30 seconds 
*Repeat with left leg 
*Repeat entire sequence 2 times 
 
Hamstring Stretch  
 
 
 *Lie on your back  
*Clasp your right thigh and pull it toward you 
*Extend your knee, keeping your back and thigh still, until you feel a gentle stretch in the back of your right thigh 
*Hold stretch 30 seconds, return to start position 
        *Repeat with left leg 
        *Repeat entire sequence 2 times 
 
 
Knee Flexion, Face lying  
                        
 
 
 
*Lie face down with your legs straight and relatively close together 
*Bend your right knee 
*Don’t let your back move as you bend your knee 
*Hold for 30 seconds then return your leg to starting position 
*Repeat with left leg 
*Repeat entire sequence 2 times 
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Hands and Knees Rocking Back  
 
 
 
 
 
 
*Get on your hands and knees 
*Rock back toward your heels, keeping your back straight 
*Return to start position 
*Repeat 2 times 
 
 
 
Standing Calf Stretch  
 
 
 
 
 
 
 
 
 
*Stand facing the wall 
*Lean to the wall and place right foot forward 
*Make sure your foot is facing straight forward, not turned out to the side 
*Keeping your back heel on the ground, lean forward till gentle stretch is felt in your calf 
*Hold stretch 30 seconds, return to start position 
*Repeat with left leg 
*Repeat entire sequence 2 times 
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Level 1 Level 2 Level 3 Level 4 Level 5 Level 6 
1. Toe Crunches, on mat 
     *10 reps 
 
2. One-leg stand with 
bilateral hand support  
  *30 seconds, 2 times 
 
 
3.  Step sideways and 
then step backwards 
with one hand support 
     *10 steps (across 
room), 2 times each 
 
 
 
4. 2 leg  heel stand (toes 
up) , back against wall 
    *5 reps 
 
 
5. 2 leg toe raises (heels 
up)  
    *5 reps 
 
6. Sit to stand 
    *3 reps 
 
 
7.  step ups, with two 
hand support  
    *10 reps 
1. Toe Crunches, on mat 
*15 reps 
 
2. One-leg stand with 
one hand support  
    *30 seconds, 2 times 
 
 
3. Step sideways and 
then step backwards 
with no hand support 
     *10 steps (across 
room), 2 times each 
 
 
 
4. 2 leg  heel stand (toes 
up), back against wall 
    *10 reps 
 
 
5. 2 leg toe raises  
   *10 reps 
 
 
6. Sit to stand 
*5 reps 
 
 
7. step ups, with one 
hand support 
*10 reps 
1. Toe Crunches, on mat 
*20 reps 
 
2. One-leg stand no 
hand support 
    *30 seconds, 2 times 
 
 
3. Step sideways on 
exercise mat, and then 
backwards on exercise 
mat with one hand 
support   *10 steps, 
(across room), 2 times 
each 
 
4. 2 leg  heel stand (toes 
up), back against wall 
    *15 reps 
 
 
5. 2 leg toe raises 
     *15 reps  
 
 
6. Sit to stand 
*7 reps 
 
 
7. step ups, with no 
hand support 
*10 reps 
1. Toe Crunches, on mat 
      *25 reps 
 
2. Stand with 2 feet on 
balance disc, bilateral 
hand support 
     *30 seconds, 2 times 
 
3. Step sideways on 
exercise mat, and then 
backwards on exercise 
mat with one hand 
support     *10 steps, 
(across room), 2 times 
each 
 
4.  2 leg  heel stand 
(toes up), back against 
wall 
*20 reps 
 
5. 2 leg toe raises 
     *20 reps       
 
 
6. Sit to stand 
    *10 reps  
 
 
7.  stair climbing, with 
one hand support 
*up and down 5 stairs 
1. Toe Crunches, on mat 
*30 reps 
 
2. Stand with 2 feet on 
balance disc, no  hand 
support 
    *30 seconds, 2 times 
 
3.  Step over objects, no 
hand support 
    *5 objects, 3 times  
(Ok to alternate with 
level 5 content but 
increase to 3 times each) 
 
 
4. Single Leg heel stand 
(toes up), back against 
wall 
     *10 reps 
 
5. Single leg toe raises 
*5 reps each side 
 
 
6.  Sit to stand 
* 12 reps 
 
 
7. stair climbing, with 
one hand support 
*up and down 1 flight 
1. Toe Crunches, on mat 
    *35 reps 
 
2. One-leg stand on 
balance disc, with 
bilateral hand support 
   *30 seconds, 2 times 
 
3. Step over objects, no 
hand support 
    *10 objects, 3 times 
(Ok to alternate with 
level 5 content but 
increase to 3-4 times 
each) 
 
4. Single Leg Heel Stand 
(toes up), back against 
wall 
*15 reps 
 
5. Single leg toe raises 
   *10 reps each side   
     
 
6. Sit to stand 
    *15 reps 
 
 
7. stair climbing, hand 
support as needed 
*up and down up to 4 
flights 
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